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 Magnetic nanoparticles (MNPs) are used in a variety of applications, including as 
agents for magnetic resonance imaging, generation of local hyperthermia, and as 
platforms for drug delivery.  Iron-based MNPs are often coated with a shell, such as silica 
or gold, to increase biocompatibility for drug delivery applications.  Many MNPs used 
for cancer therapy rely on either an internal trigger, such as a difference in pH, or an 
external trigger, such as light or an alternating magnetic field (AMF), to cause release of 
a payload, typically a chemotherapeutic drug.  Internal triggers are appealing because 
drug release can be targeted to a tumor environment, but a major drawback is untriggered 
release, or release prior to reaching the targeted area.  To address the problem of 
untriggered release, researchers have explored the use of thermally responsive triggers on 
iron oxide nanoparticles.  In these cases, payload release occurs as a result of local 
hyperthermia that is induced by application of an alternating magnetic field.  NP-linker-
drug motifs containing an azo functionality or a substructure prone to retro-Diels Alder 
reaction are examples of thermally responsive triggers.  This thesis work expands AMF-
mediated drug delivery by demonstrating a new mechanism for substrate release: 
intramolecular cyclization of a linking tether between payload and nanoparticle.  
Described is a linker system (LS) fitted with a thiol moiety, a secondary amine, carbonate 
  vi 
functionality, and a payload.  Attachment of the linker system to gold-coated iron oxide 
nanoparticles delivers a thermally responsive drug delivery system (Fe@Au-LS-drug).  
On exposure to an AMF, the magnetic nanoparticles generate heat that powers 
cyclization of the amine onto the carbonate for payload release to occur.  The cyclization 
mechanism was confirmed by synthesis and testing of an amine-free linker to rule out 
carbonate hydrolysis as the mode of payload release.  Testing the system with a water-
soluble fluorophore as payload showed 40% release in response to AMF application with 
minimal release from the amine-free linker under identical conditions.  Payload release 
could be increased to nearly 100% by addition of PEG-coated iron oxide nanoparticles as 
a means to increase local hyperthermia.  This work shows for the first time that the highly 
flexible process of intramolecular cyclization can serve in conjunction with magnetic 
iron-gold nanoparticles as a delivery system trigger for externally triggered applications. 
 Chapter 1 reviews the role of iron oxide nanoparticles in delivery applications and 
summarizes the challenges of drug delivery using various internally and externally 
responsive linkers.  Chapter 2 describes different methods for gold-coated iron oxide 
nanoparticle preparation and the challenges of such core-shell syntheses.  Chapter 3 
focuses on the synthesis of an amine-based linker system designed for AMF-mediated 
payload release.  Synthesis of the analogous control linker is also described.  Chapter 4 
describes studies using an AMF to cause payload release from Fe@Au-LS NPs.  Chapter 
5 presents all experimental procedures and the characterization data for key 
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CHAPTER 1 





1.2. PREPARATION METHODS 
1.3. SURFACE MODIFICATIONS 




 Nanoparticles (NPs) can be prepared using a variety of different organic or 
inorganic materials, including lipids,1 gold,2 and iron oxide.3  Common applications of 
NPs include water purification,4 catalysis,5 and as a platform for drug delivery.6  To be 
most effective in vivo, NPs must have a hydrodynamic size between 10-100 nm.7  The 
kidneys filter NPs smaller than 10 nm, and the immune system removes NPs greater than 
100 nm via phagocytosis.  Of particular interest to us are iron oxide NPs, which are made 
of Fe3O4 or the oxidized form γ-Fe2O3.  Both of these oxides are magnetic.  Researchers 
have exploited the magnetic properties of Fe3O4 NPs in a variety of ways, particularly in 
magnetic resonance imaging,8 induction of hyperthermia,9 and drug delivery.4 
 Magnetic resonance (MR) imaging is a common practice for non-invasive 
examination of the body.  Similar to proton nuclear magnetic resonance, MR imaging 
relies on the alignment, excitation, and subsequent relaxation of the protons of water 
molecules within the body.  Protons of water molecules within different tissues have 
different relaxation times, which allows for contrast between tissues within the body.  
After excitation, relaxation occurs in the x-, y-, and z-axes.  Contrast agents can be 
administered to give a better image of certain tissues by changing the relaxation time of 
the protons.  Gadolinium chelates alter the longitudinal (T1) relaxation rate of 
surrounding water molecules along the z-axis.  At low concentrations, they increase the 
relaxation time of T1.  This provides positive enhancement, which leads to greater 
contrast, meaning a brighter spot (Figure 1.1a).10  Iron oxide NPs less than 30 nm alter 
the transverse (T2) relaxation rate along the xy-axis of surrounding water molecules.11   
They provide negative contrast, and are seen in the image as a dark spot (Figure 1.1b).12 
	 3 
 
Figure 1.1.  MRI contrast agents.  a. Murine SV11 brain tumor 
immediately before (left) and after (right) gadolinium-based 
contrast injection.  Adapted with permission from J. Immunol. 
2000, 165, 7293-7299. Copyright 2000 The American Association 
of Immunologists, Inc.  b. Iron oxide NP accumulation in murine 
lymphoma.  Adapted with permission from NMR Biomed. 2004, 
17, 484-499.  Copyright 2004 John Wiley and Sons. 
 
 Another appealing quality of iron oxide NPs is their ability to generate local 
hyperthermia upon exposure to an alternating magnetic field (AMF).  An AMF is created 
by an alternating current, which is a current that reverses its direction many times a 
second at regular intervals.  Currents produce magnetic fields, and when a current 
alternates its direction, the direction of the magnetic field also flips.  Once a current is 
established, the current forms a magnetic field and the magnetic NPs align with it.  The 
current is not static though; it constantly flips 180°, which oscillates the magnetic field.  
Because the NPs are magnetic, they will attempt to realign with the field as it oscillates, 






Figure 1.2.  Methods of local hyperthermia generation upon exposure to an AMF. 
 
Heat from exposure to an AMF is generated through a hysteresis loss, which is the 
reversal of the NPs as a whole.  This can be broken down into two different models: 
Néelian relaxation and Brownian relaxation.  Néelian relaxation is due to the individual 
movement of each nanoparticle dipole, whereas Brownian relaxation is due to the 
physical rotation of the nanoparticle itself.13  The heat generated is quantified as specific 
loss power (SLP) or specific absorption rate (SAR). These terms are interchangeable 
because both are measurements of heat dissipation per unit mass of magnetic 
nanoparticles in an AMF.14		This value can vary depending on a variety of factors, such 
as NP size, 15  viscosity of supernatant, 16  magnetic field strength and frequency, 17 
concentration,11 and polydispersity.18 
Local hyperthermia is especially important in some forms of cancer therapy.  
Solid tumor cells have poor vasculature that leads to hypoxia and low pH, making 
cancerous cells more susceptible to hyperthermia.19  Increased temperatures in or near 
tumor cells, generally between 40 °C and 45 °C, can lead to apoptosis, or cell death.  This 
	 5 
rise in temperature does not affect most healthy cells because their structured vasculature 
allows for better heat dissipation (up to 20 times increased blood flow in healthy tissue 
versus 2 times increased blood flow into cancerous cells).13  In addition, healthy cells 
produce heat shock proteins on exposure to local hyperthermia.  Heat shock proteins 
(HSP) allow proteins to refold after denaturation caused by a rise in temperature, or heat 
shock.  Cancerous cells overexpress heat shock proteins and present them on the surface 
of the cell, which then are easily lysed by killer T-cells.19 Finally, local hyperthermia as 
an adjuvant therapy increases a cell’s susceptibility to radiation treatment post AMF 
application, as seen in Table 1.1.  If the temperature within a cell reaches above 45 °C, 
cell ablation occurs.  At this temperature, both healthy and cancerous cells are affected, 
and prolonged exposure causes necrosis.20  
 











Radiotherapy 41 83% 41% 
Breast Radiotherapy 306 59% 41% 
Lung Chemotherapy 44 68% 36% 
Bladder Radiotherapy, Surgery 102 94% 67% 
Table 1.1.  Various tumor treatments with or without adjuvant thermotherapy.  The dual 
therapy shows an increase in number of patients in complete remission after primary 
treatment with adjuvant hyperthermia treatment versus without hyperthermia.  Adapted 
with permission from Ann. Oncol. 2002, 13, 1173-1184.  Copyright 2002 Oxford 
University Press. 
 
The first study utilizing localized hyperthermia generation for prostate cancer was 
done in Germany over 10 years ago.21  Johannsen et al. injected iron oxide NPs with an 
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aminosilane-type shell into the prostate of a 67 year-old man with locally recurrent 
prostate cancer and exposed him to an AMF (Figure 1.3).  The temperature of the 
prostate rose between 40 °C and 48.5 °C during the first treatment.  Six weeks after NP 
injection, AMF treatment was repeated without new injection and the intraprostatic 
temperature was between 39.4 °C and 42.5 °C. 
 
Figure 1.3.  Alternating magnetic field applicator for human use 
(MFH300F, MagForce® Nanotechnologies GmbH, Berlin).  
Adapted with permission from Int. J. Hyperthermia 2005, 21, 637-
647.  Copyright 2005 Taylor and Francis Group.   
 
Local hyperthermia can be effective for cancer treatments, but it is often difficult to 
completely eradicate the tumor, especially in the case of prostate cancer, where the 
distribution of NPs is poor.  Despite the initial shortcomings, Johannsen et al.22 continued 
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to evaluate the quality of life after iron oxide NPs hyperthermia treatments. They found 
no significant impairment of the quality of life.  The coated iron oxide NPs had no 
systemic toxicity, but, as seen before, the distribution of NPs within the prostate was 
poor.  This created hotspots within the tumor, up to 55 °C, and thus necessitated that the 
power of the AMF be significantly lowered compared to other studies (i.e., 4-5 kA/m for 
prostate versus 10-14 kA/m for brain tumors) to limit discomfort and skin reactions.  Of 
the 15 most commonly used FDA-approved nanotherapeutics in the past 20 years, few 
involve using only iron oxide NPs, and none appear to use hyperthermia as the foremost 












Severe Combined Immunodeficiency 
Disease* 1990 
Oncospar Pegylated Asparaginase Acute Lymphoblastic Leukemia 1994 
Doxil Liposomal Doxorubicin 
Kaposi’s Sarcoma, Ovarian Cancer, 









Copaxone Glutaramer Acetate Multiple Sclerosis 1996 
Ferumoxsil Siloxane-Coated Iron Oxide Oral Contrast Agent 1997 
PegIntron Pegylated Interferon α-2b Hepatitis C 2001 
Pegasys Pegylated Interferon α-2a Hepatitis B, C 2002 
Neulasta Pegylated Filgastrim Chemotherapy-induced Neutropenia 2002 
Abraxane Albumin Bound Paclitaxel 






Anemia of Chronic Kidney Disease 2007 
Depocyte Liposomal Cytarabine Lymphomtous Meningitis 2007 
Exparel Liposomal Bupivacaine Post-operative Pain 2011 
Sienna+ Dextran-Coated Iron Oxide Sentinal Lymphnode Mapping* 2011 
Marquibo Liposomal Vincrisitine Adult Acute Myelogenous Leukemia 2012 
 
Table 1.2.  Most commonly used FDA-approved nanotherapeutics; highlighted entries 
show use of iron oxide NPs.  * indicate approval by European Regulatory Agency but not 
FDA.  Adapted with permission from Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 





Current nanotherapeutics and clinical studies focus on delivery of chemotherapeutic 
drugs in a NP formulation. 23   Many clinicians believe that NP formulation of drugs will 
decrease systemic toxicity as well as increase efficacy.  To date, only the former has been 
proven true.  In the case of NP-mediated hyperthermic treatment of cancer, it appears 
likely that a combination of local hyperthermia and drug delivery will be necessary for 
optimal cancer eradication – this is the basis of the present thesis work.   
Iron oxide NPs are an ideal platform for drug delivery.  However, direct binding 
of drugs to iron oxide NPs is not common because of the limited reactivity of the NP 
surface.    As a result, iron oxide NPs are often coated with a shell.  In one example, 
Mattingly et al.24 used a surrounding cationic lipid bilayer to host small molecules, such 
as doxorubicin (Dox), an anti-cancer agent (Figure 1.4).  Efficacy of this system was 
explored using in vitro studies on MCF-7 breast cancer cells.   After incubation at 37 °C 
for 2 hours, the magnetic liposomes released Dox and caused >90% cell death.  Other 
common coatings include silica or gold.  Core-shell NPs of this type will be discussed in 





Figure 1.4.  Magnetic liposomes for drug delivery.  Dox 
release and >90% cell death was seen after incubation at 37 
°C for 2 hours.  Adapted with permission from Langmuir 
2015, 31, 3326-3332.  Copyright 2015 American Chemical 
Society. 
 
Several researchers have exploited the local hyperthermia generated by iron oxide 
NPs upon exposure to an AMF as a mechanism (i.e., trigger) for drug release.  A popular 
coating for iron oxide NPs is mesoporous silica (Figure 1.5).  Thomas et al.25 designed 
mesoporous silica NPs with zinc-doped iron oxide as the core.  A “thread” (consisting of 
N-(6-N-aminohexyl)aminomethyltriethoxysilane) was chemically attached to the inside 
of the pores, followed by drug loading within the pores of the silica NPs.  The pores then 
were capped with cucurbit[6]uril, which is a macrocycle that interacts electrostatically 
with the “thread” molecule to prevent drug release.  Upon exposure to an AMF, the 
generated local hyperthermia helped the caps to overcome their attraction to the “thread” 





Figure 1.5.  Mesoporous silica NPs for drug delivery.  Doxorubicin is loaded into pores 
that then were sealed by addition of a “cap” (4).  Upon exposure to an AMF (5), the cap 
is displaced and the drug is released.  Adapted with permission from J. Am. Chem. Soc. 
2010, 132, 10623-10625.  Copyright 2010 American Chemical Society. 
 
 
In another example, thermoresponsive hybrid nanogels were prepared by Cezar et al.26  
This group designed a ferrogel from alginate and iron oxide NPs to be solid at room 
temperature (Figure 1.6, left).  After exposure to an AMF (Figure 1.6, right), the hydrogel 
deforms.  The biphasic hydrogel was loaded with mitoxantrone, an antineoplastic agent, 
through ionic interactions with alginate.  Deformation of the hydrogel led to diffuse drug 




Figure 1.6.  Biphasic hydrogel for drug release.  After synthesis, the gel remains solid 
(left), but upon exposure to an AMF, the hydrogel deforms and releases its payload.  
Adapted with permission from Adv. Heathc. Mater. 2014, 3, 1869-1876.  Copyright 2014 
John Wiley and Sons. 
 
1.2. PREPARATION METHODS  
Iron oxide NPs can be prepared in a variety of ways.  One simple, highly used 
method is co-precipitation of iron salts.27  This method relies on the addition of the iron 
salts Fe2+/Fe3+ in a 2:1 ratio to a basic aqueous medium to yield Fe3O4.  The method is 
straightforward, is done within minutes, and gives high yields of NPs.  However, poor 
shape control, oxidation, and aggregation are all problems associated with the co-
precipitation method.  Riaz et al.28 explored the size and shape of iron oxide NPs in 
relation to pH by varying the amount of sodium hydroxide in solution.  At low pH (pH = 
2), the NPs had diameters of 25 nm, while at high pH (pH =10), the NPs had diameters of 
100 nm.  At pH = 8, the Fe3O4 NPs were non-uniform, varying 50-100 nm in diameter.  
A former colleague in the Nantz group, Dr. Stephanie Mattingly, measured particle 
surface charge by varying washing steps after NP synthesis and isolation and then 
examined the NP zeta potential. 29   Different washing methods, such as dilute 
hydrochloric acid versus neutral water, significantly altered the resultant NP surface 
charges.  Rinsing once with neutral water after the co-precipitation method gave anionic 
NPs, while rinsing with dilute hydrochloric acid gave positively charged NPs, as might 
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be expected.  NPs that have a surface charge tend not to aggregate because of ionic 
repulsion.  When the NPs were rinsed multiple times with neutral water, as is often 
described in Methods sections of literature preparations, the NPs had a neutral charge, 
which can lead to aggregation.  To help achieve monodispersion and avoid aggregation, a 
thermal decomposition method was developed.30  This method is performed in non-
aqueous media and coats the NPs with an organic ligand, which decreases aggregation.  
NPs made in this way also have a very narrow size distribution, good shape control, and 
relatively high yields.  Unlike the co-precipitaiton method, the reaction requires high 
temperatures (e.g., 210 °C-320 °C), an inert atmosphere, and longer reaction times.  Also, 
because the reaction is not performed in water, further steps are necessary to make the 
resultant NPs water-soluble.31 Other methods for NP synthesis include microemulsion32 
and hydrothermal syntheses. 33 
 
1.3. SURFACE MODIFICATIONS 
 In addition to the need for shells to enable convenient substrate attachments, other 
problems have been noted using “naked” iron oxide NPs.  Without surface modification, 
iron oxide NPs are degraded into ferrous Fe (II) and ferric Fe (III) by the liver or spleen34 
or cause oxidative stress, as seen in in vivo studies by Chahinez et al.35  Surface 
modifications allow for biocompatibility, and often include organic ligands, such as 
polyethylene glycol (PEG)36 and chitosan,37 or inorganic coatings, such as silica38 or 
gold.39   These modifications change the iron oxide surface, which allows for the 
attachment of a variety of molecules, such as drugs, targeting agents, or antibodies. 
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 Silica is widely used to modify iron oxide NPs because it is hydrophilic, which 
aids in aqueous solvation, it helps prevent aggregation through electrostatic repulsions, 
and it provides a surface that is more amenable to attachment of molecules.40  One of the 
most popular methods to coat iron oxide with silica is the Stöber method38 in which the 
iron oxide nanoparticles are dispersed in a water/ethanol solution.  Formation of the silica 
shell happens after hydrolysis of a silica precursor, such as tetraethoxysilane (TEOS), 
followed by condensation of the siloxane onto the surface of the iron oxide NPs.  This 
method is attractive because the silica shell thickness can be fine-tuned based on the 
amount of alkoxysilane added.41  Recent examples of silica-coated iron oxide NPs in drug 
delivery include work by Hwang et al.,42 Moorthy et al.,43 and Zhang et al.44 
 Gold nanoparticles are also widely employed in drug delivery because gold is an 
inert noble metal with excellent biocompatibility.  Gold is becoming popular as a shell 
coating of iron oxide NPs principally for this reason, although the ease of attachment of 
substrates via thiol methodology is another strong driving force.45  Iron oxide-gold core-
shell (Fe@Au) NPs can be synthesized in a few ways, namely a bilayer method via 
aqueous or thermal decomposition, or a multilayer method using a “glue” molecule to 
attach a gold shell.39  In the aqueous bilayer method, the iron oxide core is combined with 
chloroauric acid (HAuCl4) and the gold is reduced chemically.  Common reducing agents 
include sodium borohydride,46 citrate,47 and ascorbic acid.48  A second common bilayer 
method is thermal decomposition, where hydrophobic iron oxide NPs are combined with 
oleic acid, oleyl amine, and gold (III) acetate, then heated in a high boiling organic 
solvent.49  This method does require further modification to the shell to make the Fe@Au 
NPs water-soluble.  Though prevalent in the literature, bilayer methods are challenging 
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because of the difficulty of gold deposition on the iron oxide core, as well as the 
formation of gold nanoparticles (GNPs) in the process of shell formation.  To overcome 
this challenge, researchers have explored the use of molecules that strongly attach to both 
iron oxide and gold to serve as a  “glue” that binds the metals together.  Often, this 
method involves using gold nanoseeds in the form of amine-terminated molecules as 
nucleation points onto which the gold can reduce.  After synthesis, ligands that can bind 
to the gold shell, namely amines or thiols, both of which form strong bonds with gold,50 
are added to coat the NP surface.   
 
1.4. DRUG DELIVERY CHALLENGES  
Drug delivery systems utilize a stimulus to deliver a drug at a specific time and 
location within the body to avoid side effects due to systemic distribution.  A common 
chemotherapeutic agent used in the treatment of cancer is Dox, which induces apoptosis 
in replicating cells.51  The cells that are affected the most are rapidly growing cancer 
cells, but rapidly growing non-cancerous cells are affected as well.  When administered 
intravenously, common side effects include hair loss and digestive issues.  A serious side 
effect of Dox in large quantities (i.e., 500-600 mg/m2) includes myocardial toxicity, 
which can lead to congestive heart failure or death.52  Because of these limitations, better 
spacial and temporal drug delivery is the next step in cancer treatment.  Precise delivery 
of drugs to cancer cells, so that healthy cells are minimally affected, reduces the side 
effects seen with systemic distribution.  Because of this, the Dox dosage loaded onto a 
nanoparticle can be decreased because healthy cells are not destroyed as they were with 
systemic distribution.  In what we believe will be a key advance, Dox tethered to iron 
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oxide NPs can be used in combination with thermotherapy – cancer cells are more 
susceptible to chemotherapy after thermotherapy.19   
 
Scheme 1.1.  Common conjugations of Dox.  Dox can react with a primary amine (R, R’ 
= carbon), hydrazine (R = NH, R’ = carbon), or acyl hydrazine (R = NH, R’ = acyl) to 
form an imine, hydrazone, or acyl hydrazone, respectively. 
 
Dox attachment to NPs can be through ionic interaction or covalent bonds.53  Of 
particular interest to us is covalent attachment. One way to load Dox onto NPs 
conveniently is through its C(13) carbonyl moiety (Scheme 1.1).  A hydrazine compound 
can react with Dox to form a hydrazone linkage, which cleaves under acidic conditions.  
This is an ideal internal stimulus, since the area surrounding cancer cells is slightly more 
acidic, pH 5-6, than physiological conditions, pH 7.4.54  Aryal et al.55 attached an 
equimolar amount of PEG-thiol and DOX-acyl hydrazone to gold nanoparticles (Figure 
1.7a) and showed 80% Dox release after 5 hours at pH 5.3.  Mohammad et al.56 attached 
Dox to Fe@Au via cysteamine to form an imine (Figure 1.7b), which are cleaved in 
acidic conditions as well.  Release of Dox is seen, but only 56% is seen at the extremely 
























AMF at various power settings, where the highest setting (430 Hz) released 72% Dox 
after 3 hours. 
 
Figure 1.7.  a. Dox attached to gold NPs via acyl hydrazone linkage.  After 5 hours at pH 
5.3, 80% release was seen.  Adapted with permission from J. Mater. Chem. 2009, 19, 
7879-7884.  Copyright 2009 Royal Society of Chemistry.  b. Dox attached to Fe@Au 
NPs via imine bond.  At extremely low pH with application of an AMF at 430 Hz, 72% 
release was seen.  Adapted with permission from J. Colloid Interface Sci. 2014, 434, 89-
97.  Copyright 2014 Elsevier.   
 
 Despite the appeal of internally triggered drug release, it is not ideal.  In each of 
the above “internal release” studies, Dox escape from the carrier was seen, even at 
physiological pH (10% for Aryal and 30% for Mohammad).  This problem of untriggered 
release is critical.  If NPs are injected into patients intravenously, they passively pool in 
the tumor though the enhanced permeation and retention (EPR) effect.  Enhanced 

























lymphatic drainage.57  The pooling process is not instantaneous; it takes time for blood to 
circulate and NPs to retain near the tumor.  As the NPs circulate, though, they release 
drugs in a systemic type fashion rather than only near tumor cells.  The advantage in 
using a delivery system is lost.  The payload released during circulation may or may not 
kill cancer cells as intended (i.e., they are likely to affect other rapidly growing, healthy 
cells, as seen in systemic distribution), meaning more drug must be loaded onto the NPs 
to deliver the initial intended dosage to the target area.  This, in turn, would lead to a 
greater concentration of untriggered release systemically, making this delivery system 
only slightly better than systemic chemotherapeutic distribution. 
Because an internal trigger cannot be easily controlled, the use of an external 
trigger, such as an AMF, is needed for precise payload release.  One such method is the 
use of a thermally labile group that would release payload upon triggering.  In recent 
years, researchers have explored the azo functionality58,59 as well as a retro-Diels Alder 
reaction60,61 for payload release, as discussed below.  
The azo functionality decomposes at high temperatures, generally above 150 °C.62  
The mechanism for azo decomposition is through a radical reaction, as outlined in 
Scheme 1.2.63  There are 3 stages in a radical reaction: initiation, propagation, and 
termination.  Radical formation is initiated by heat generated upon NP exposure to AMF, 
creating a carbon and nitrogen radical (Scheme 1.2a).  In the next step, a new radical is 
formed and nitrogen is expelled (Scheme 1.2b).  Termination is caused by the 





Scheme 1.2.  Thermal decomposition of azo functionality.  a. 
Initiation of radical formation is caused heat to form a carbon 
and nitrogen radical.  b. The nitrogen radical reacts to expel N2 
and a new carbon radical.  c, d. Termination occurs when 
radicals combine to form new bonds.  Adapted with permission 
from Int. J. Chem. Kinet. 1984, 16, 767-779.  Copyright 1984 
John Wiley and Sons.   
 
Researchers have already explored the use of thermally labile linkers attached to 
iron oxide NPs for payload release.  Riedinger et al.58 first explored the distance at which 
an azo moiety would decompose when iron oxide NPs were exposed to an AMF.  For 
ease of detection, they initially used fluoresceineamine, then Dox after optimization.  
Each step of the linker was built onto the NP, as opposed to complete synthesis first, with 
attachment to the NP last. 
 
N N N N +











Scheme 1.3.  Thermal decomposition of azo linkage (red) between spacer attached to 
iron oxide NP (black) and fluorophore (green).  Adapted with permission Nano Lett. 
2013, 13, 2399-2406.  Copyright 2013 American Chemical Society.   
 
 
As seen in Scheme 1.3, gallic acid was derivatized with different lengths of PEG for 
attachment to iron oxide NPs, then the azo functionality was attached followed by 
attachment of the fluorophore via an amide bond.  The length of spacer between the NP 
and the azo functionality did not significantly change the amount of azo decomposition 
when held at a constant temperature.  When the NP-linker system was exposed to an 
AMF for 1 hour, the shorter PEG spacer released more fluorophore.  It can be inferred 
from the data that the carbon-based free radicals formed did not combine as seen in 
Scheme 1.2d.  If this were so, the fluorophore would remain on the NP and would not 
show release.  The fluorescence release data for the shorter PEG spacer corresponded to a 
larger change in temperature compared to the longer PEG spacer (i.e., 40 K vs 10 K 













































temperature change was detected 0-3 nm from the surface of the iron oxide NP, with 
significant exponential decay as the distance increased.  More recently, Romero et al.59 
used thermal decomposition of a short linker with an azo group for rapid release of a 
fluorescent dye, CG633.  Upon exposure to an AMF (500 kHz and 15 kA m-1), nearly 
entire release was seen after only 10 seconds for NPs with a diameter of 20 nm.  This 
technology was used to release a pharmacological agent, allyl isothiocyanate, for neuron 
excitement.  After exposure to an AMF, rapid Ca2+ influx was noted, indicative of neuron 
excitation.  
In another strategy, N’Guyen et al.60 designed a retro-Diels Alder (DA) linker for 
delivery of a fluorophore, rhodamine, without inducing a significant temperature increase 
to the bulk solution.  At higher temperatures, the synthesized linker undergoes retro-DA 
reaction.  The requisite higher temperature is induced when NPs are exposed to an AMF.  
The linker design is shown in Scheme 1.4.  The linker was synthesized prior to loading 
on the iron oxide NPs, with installation of the fluorophore performed after linker loading.  
A phosphonic acid ligand was used for attachment to iron oxide NPs (4, Scheme 1.4).  A 
hydrophilic polymer was attached to the linker via a 1,3-dipolar cycloaddition.  The azide 
was attached to the polymer, and the alkyne was attached to the linker.  Under typical 
copper-catalyzed azide-alkyne cycloaddition, the two moieties reacted in 3+2 fashion to 
form the corresponding triazole (2, Scheme 1.4).  Rhodamine was attached via DA (5, 
Scheme 1.4) with 85 % attachment confirmed via NMR analysis.  The loaded NPs were 
exposed to AMF (frequency 332.5 kHz, magnetic field strength 11.3 kAm-1) for 10 
minutes.  Release of 3 % and 5 % for 2.5 x 10-3 wt % and 2.5 x 10-3 wt %, respectively, 
could be seen without any significant increase in bulk solution temperature. 
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Scheme 1.4.  Synthesis of a retro-DA linker with hydrophilic polymer attachment via 
1,3-dipolar cycloaddition and DA for fluorophore attachment onto iron oxide NPs.  
Adapted with permission Angew. Chem. Int. Ed. 2013, 52, 14152-14156.  Copyright 
2013 John Wiley and Sons.   
 
In another example, Hammad et al.61 designed a retro-Diels Alder (DA) linker for 
delivery of Dox.  The linker-drug was attached to Zn0.4Co0.6Fe2O4@Zn0.4Mn0.6Fe2O4 
core/shell NPs by means of alendronic acid-iron interactions.  The zinc-cobalt and zinc-
manganese doped NPs have a higher SAR than pure iron oxide NPs, meaning they have 
enhanced magnetic heat inducing properties and induced local hyperthermia to a greater 



















































































utilizing furan and maleimide as the diene and dieneophile, respectively.  As seen with 
retro-DA linker design by N’Guyen et al., higher temperatures caused the linker to 
undergo a retro-DA reaction.  The requisite higher temperature can be induced when NPs 
are exposed to an AMF.  The linker design is shown in Scheme 1.5.  Like with Reidinger 
et al., the linker was synthesized directly on the iron oxide NPs rather than complete 
synthesis of the linker prior to attachment.  Alendronic acid served as the means for 
attachment to NPs (2, Scheme 1.5) and Dox was attached via an amide bond (5, Scheme 
1.5) with confirmation of loading via FT-IR analysis.  The loaded NPs were exposed to 
AMF (frequency 1950 kHz, power 6200 W) for 5 minutes.  The temperature of the 
solution reached 50 °C after 5 minutes of exposure to the AMF and remained at 50 °C for 
10 minutes after exposure was ceased.  Dox release was ~45% after the 5 minutes of 
exposure to AMF, and release increased to greater than 90% Dox release in the 10 
minutes after AMF exposure was stopped.  This work with thermally labile linkers 
ultimately encouraged our pursuit of a short linker that would require significant thermal 
energy for rapid payload release. 
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Scheme 1.5.  Synthesis of a retro-DA linker onto zinc-cobalt-iron NPs.  Adapted from 




































































 Combining local hyperthermia treatment with drug delivery by using a single 
agent to accomplish both tasks is the next generation of cancer treatment.  The use of a 
thermally labile linker attached to biocompatible NPs, specifically Fe@Au NPs, to 
release a payload based on an external stimulus such as AMF is not prevalent in literature 
and should be explored in greater depth and breadth.  We designed a thermally 
responsive linker for attachment to Fe@Au NPs which utilized the ability of iron oxide 
NPs to create a local hyperthermia upon exposure to AMF.  The generated local 
hyperthermia promoted intramolecular cyclization and caused linker cleavage (i.e., drug 
delivery) as seen in Figure 1.8, thus providing thermotherapy and drug delivery 





Figure 1.8.  Overall pictoral representation of thesis work.  I: Fe@Au NPs, II: Dual NP 
system of gold NPs and water-soluble iron oxide NPs.  Left panel: NPs at physiological 
temperature (37 ºC), no release of payload.  Middle panel: Application of AMF to 
induce local hyperthermia of iron oxide, bulk solution temperature 40-45 ºC.  Right 
panel: Payload released from NPs into solution. 																																																									
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CHAPTER 2 
CORE-SHELL NANOPARTICLE PREPARATION 
________________________________________________________________________ 
2.1. INTRODUCTION 
2.2. GOLD SEEDED IRON OXIDE NANOPARTICLES 
2.3. CORE-SHELL IRON OXIDE-GOLD NANOPARTICLES 






Figure 2.1.  Gold-coated iron oxide nanoparticle. 
 
Gold-coated iron oxide NPs (Fe@Au, Figure 2.1) can be synthesized in a variety 
of ways.1, 2  The medium in which the gold coating is applied can be either aqueous or 
organic, and the coating can be either deposited directly onto an iron oxide core or 
indirectly, by application using a “glue” material to aid the coating process.  Each 
approach uses gold in a +3 oxidation state, typically gold (III) chloride hydrate or gold 
(III) acetate, and a reducing agent, such as sodium borohydride, sodium citrate, or oleyl 
amine.  The reducing agent reduces gold (III) to metallic gold (0), starting with a 
nucleation step followed by deposition and growth on the iron oxide NP to become the 
shell.3,4  As mentioned previously, coating iron oxide NPs with gold imparts adequate 
biocompatibility to the resultant NPs and allows for flexible NP functionalization through 
reactions with sulfhydryl (-SH) compounds.  Another common functionalization method 
includes the use of amines, as discussed by Grabar et al.5 in their report on 2D arrays of 
colloidal gold NPs for surface-enhanced Raman scattering.  The ready coating by thiols 
and amines is due to the prominent interaction between amino or sulfhydryl groups and 





and they concluded that the interaction between amino and gold is weakly covalent.  This 
is unlike the thiol-capped gold NPs first synthesized by Brust et al.,7 who described the 
sulfhydryl and gold interaction as covalent.  More specifically, the interaction between 
sulfhydryl and gold has been explored at the nanoscale since the discovery of 
spontaneous assembly of alkanethiols on noble metals.8  A recent review by Häkkinen9 
describes the interaction as: “the sp3-type hybridization of sulfur, with two of the hybrid 
orbitals making covalent bonds to the Au(6s) electrons, as well as the important 
contributions from Au(d) electrons”.   
Prior to gold coating, the magnetic iron oxide core must be synthesized.  Methods 
for this are described in Chapter 1.  Magnetic NPs can be made of a variety of 
materials,10 including pure iron, cobalt, and nickel, but for the Fe@Au NPs of this work 
the core is made from iron oxide.  Iron oxide NPs consist primarily of magnetite (Fe3O4) 
or its oxidized form maghemite (γ-Fe2O3). Recent reviews on Fe@Au NPs1,11 discuss 
advances in the synthesis of Fe@Au NPs and claim the core for the majority of Fe@Au 
NPs described in the literature consist of Fe3O4, although γ-Fe2O3 is used as well.12  The 
process to coat γ-Fe2O3 is very similar to that of Fe3O4.  For example, Siurdyba et al.13 
used a short amino-terminated linker to coat a γ-Fe2O3 core, followed by gold nanoseed 
capture strategy and then reduced gold to form a shell, which is quite similar to work 
described later in this chapter.  The following subsection reviews methods of preparation 






Scheme 2.1.  Synthetic routes to Fe@Au NPs.  a. Direct aqueous method uses reducing 
agents such as sodium borohydride, glucose, sodium citrate, and ascorbic acid.  b. Direct 
organic method uses reducing agents such as oleyl amine and 1,2-diols.  Adapted from J. 
Chem. Commun. 2016, 52, 7528-7540.  Copyright 2016 The Royal Society of Chemistry.  
c. Indirect method, where the “glue” coating can be added in an aqueous or organic 
solvent, and the shell formation can use either direct coating method.  This “glue” is often 
an amine-terminated molecule, such as (3-aminopropyl)trimethoxysilane, 
polyphosphazene, or polyethyleneimine.  Adapted with permission from ACS Appl. 
Mater. Interfaces 2013, 5, 4586-4591.  Copyright 2013 American Chemical Society. 
a. Direct Aqueous























The most common and simplest method for direct aqueous Fe@Au NP synthesis 
involves iron oxide NPs that are gold coated by reaction in the presence of Au (III) and 
sodium citrate as both a reducing agent and capping agent, as seen in Scheme 2.1a.  As 
the Fe@Au NPs are formed, they are immediately coated with sodium citrate, preventing 
aggregation.  Other reducing agents can be used, such as sodium borohydride addition 
directly in solution followed by 3-mercaptopropionic acid capping14 or delivery of 
sodium borohydride via a micelle if microemulsion method is used,15 glucose followed 
by chitosan coating,16 or ascorbic acid, which acts as both a reducing and capping 
agent.17 
One indirect method for gold coating is to use a seeding method that tethers gold 
nanoseeds, which are GNPs with a diameter of 2-3 nm, to the iron oxide core prior to 
bulk gold deposition, as seen in Scheme 2.1c.  Seeding creates a point of nucleation for 
the gold deposition to form the shell.  An iron oxide core can be functionalized with (3-
aminopropyl)trimethoxysilane (APTMS) to give Fe3O4@APTMS.  Simple mixing of 
Fe3O4@APTMS with gold nanoseeds then enhances nanoseed attachment due to the 
strong interaction between the amino moiety and gold.18,19  In addition, a thiol moiety can 
be used for gold nanoseed attachment.  Researchers have shown greater stability of 
molecules bound to gold NPs using multiple thiol anchor points.  The Mirkin group first 
explored attachment of a cyclic dithiane-steroid linker to attach DNA onto GNPs.20  
Unlike monothiol moieties that the group studied (Figure 2.2a), the dithiane approach 
(Figure 2.2b) showed decreased susceptibility to displacement using dithiothreitol (DTT), 
a common reagent used for cleaving the gold-thiol bond.  Expanding this concept, the 
Mirkin group developed an oligonucleotide with three thiol groups attached via an acetal 
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backbone linker (Figure 2.2c),21 which had even greater stability toward displacement via 
DTT.  These syntheses provide robust attachment, but are quite complicated.  Both 
syntheses required multiple steps for DNA derivatization for attachment of the thiol 
motifs.  Sharma et al.22 performed a one-step derivatization of DNA for attachment to 
gold nanoparticles (Figure 2.2d).  They reacted amine-modified oligonucleotides with 
carbon disulfide (CS2), which formed a dithiocarbamate in situ, followed by incubation 
with gold nanoseeds.  This created DNA-modified, coated gold nanoparticles using a 
bidentate attachment, which showed increased robustness toward DTT in comparison to 
ligands with monodentate attachment.  After only 3 minutes of incubation with DTT, the 
monodentate DNA-gold (Figure 2.1e) began to aggregate, as seen in the UV-Vis, 






Figure 2.2.  DNA modified ligands attached via (a, e) monothiol, (b) dithiol, (c) 
trithiol, or (d) dithiocarbamate.  Adapted from the following sources: Bioconjugate 
Chem. 2000, 11, 289-291.  Copyright 2000 American Chemical Society.  Nucleic 
Acids Res. 2002, 30, 1558-1562.  Copyright 2002, Oxford University Press.  Chem. 
Commun. 2008, 2140.  Copyright 2008, Royal Society of Chemistry. 
 
 
Another common Fe@Au NP synthesis uses high temperatures and organic 
solvents to prepare hydrophobic NPs.  Wang et al. 23  first utilized a thermal 
decomposition method to form such hydrophobic Fe@Au NPs.  In a high boiling solvent, 
such as phenyl ether at 185 °C, organic soluble iron oxide NPs were added to gold (III) 










































by the addition of a 1,2-diol and oleic acid.  As seen in Scheme 2.1b, the coated iron 
oxide NPs are stripped of the coating before gold is reduced onto the surface.  Oleyl 
amine then caps the gold as it is deposited onto the iron oxide until the entire shell is 
formed.  The NPs were purified via centrifugation and resuspended in hexane in the 
presence of oleic acid and oleyl amine.  Alonso-Cristobal et al.24 explored the effects of 
varying the iron oxide:gold (III) acetate ratio and reaction temperature with regards to the 
gold shell thickness.  They found that the ratio did not affect the thickness of the gold 
shell; rather, a larger amount of gold (III) acetate led to homogeneous nucleation, which 
created gold NPs rather than coat the iron oxide NPs.  This is a key observation that has 
importance for this thesis work, as discussed in a later chapter.  The optimal ratio of iron 
oxide:gold (III) acetate was 0.05 mmol:3.7 mmol for iron oxide NPs with a mean 
diameter of 7.5 nm.  They also showed that a reaction temperature between 190 °C and 
210 °C did not influence the gold shell thickness, but between 230 °C and 270 °C showed 
significant gold shell thickness, from 3 nm at lower temperatures to 10 nm at higher 
temperatures. 
Though many researchers claim success with a variety of methods, it remains 
difficult to control deposition of gold onto iron NPs.  This is due to the differences in 
surface energy between iron oxide and gold11,25 that oftentimes lead to the undesired co-
formation of GNPs.  GNPs are caused by autonucleation.  They also aggregate once 
formed, thus complicating methods of purification.  Undesired GNPs can be minimized 
through optimization of the ratio of iron oxide to gold, although too little gold precursor 
can lead to incomplete coating and thus exposure of the iron oxide NP.  Conditions need 
to be carefully controlled in order to maximize complete gold coating without GNP 
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formation – this is the key challenge in the field.  If GNPs are formed, though, one 
method of separation from Fe@Au NPs is to use centrifugation to give monodispersed 
Fe@Au NPs.23 
 
2.2. GOLD SEEDED IRON OXIDE NANOPARTICLES 
We first sought to prepare Fe@Au NPs via gold seeding followed by a Au (III) 
reduction approach to try to thwart the major problem of GNP formation faced in many 
of the other methods.  Our first idea to make gold-coated iron oxide nanoparticles was 
based on some previous work done by Dr. Stephanie Mattingly in our lab.26  In this work, 
she sought to modify the iron oxide nanoparticles by reaction with CS2 to yield xanthate 
functionality that would then serve as the “glue” for subsequent small molecule 
attachment (Scheme 2.2b).  Xanthates are typically formed when organic alcohols in base 
react with carbon disulfide followed by alkylation (Scheme 2.2a).  Mattingly investigated 
functionalization of the oxides on the surface of iron oxide nanoparticles by reaction with 
excess carbon disulfide.  Ultimately, this work was unsuccessful but, upon further 
research, we discovered related modifications to iron oxide NPs using CS2 that have been 
reported and showed promise. 27   Instead of reacting naked iron oxide with CS2 to form a 
xanthate, Lopes et al. functionalized iron oxide NPs with terminal primary amines that 






Scheme 2.2.  a. Traditional xanthate ester formation.  b. Ferric xanthate 
variation.  c. Dithiocarbamate formation (1) with subsequent gold seeding (2). 
 
Lopes et al. used this approach (i.e., coatings with a siloxydithiocarbamate) to 
scavenge colloid gold from an aqueous solution for purposes of water purification 
(Scheme 2.2c, step 2).  The reacted solution was then exposed to an external permanent 
magnet, and the water was purified of the reacted gold nanoparticles.  In another 
example, Montazerabadi et al.18 used a gold seeding method (Scheme 2.2c, step 2) 
followed by Au (III) reduction to form Fe@Au NPs for MRI contrast.  The following 
describes this procedure, which was followed for synthesis of Fe@Au NPs via a seeding 
method. 
 Following a modified procedure by Montazerabadi et al.,18 we used a short linker, 
3-aminopropyl(triethoxysilane) (APTES), to coat the iron oxide NPs.  Briefly, we reacted 
excess APTES with iron oxide NPs that were prepared according to the method of 










































Mikhaylova et al.28  The resultant reaction mixture was sonicated for 30 minutes.  The 
suspension was then rapidly stirred and heated at 60 °C in a sealed tube for 4 hours, 
followed by magnetic separation and washing with methanol to remove excess APTES.  
Comparison of the FT-IR spectrum of the starting “naked” iron oxide nanoparticles with 
that of the APTES-reacted nanoparticles (Figure 2.3) suggests the NPs were modified as 
desired, principally due to the appearance of C-H stretch (2929 cm-1 and 2840 cm-1), N-H 
stretch (3358 cm-1), and characteristic Si-O-R stretching (1043 cm-1). 
 
Figure 2.3.  Comparison of FT-IR spectra of Fe3O4 
NPs   (top)   and   Fe3O4@APTES  NPs  (bottom). 
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With APTES-coated iron oxide nanoparticles in hand, we next examined how to 
attach the gold nanoseeds.  In an effort to maximize attachment, we chose to follow a 
modified synthesis provided by Sharma et al.,22 utilizing the bidentate chelation afforded 
by reaction of the amine with CS2.  After reacting Fe3O4@APTES in borate buffer with 
saturated aqueous carbon disulfide, we added excess aqueous gold nanoseeds (2-3 nm).  
Gold nanoseeds were provided as a gift by Dr. Martin O’Toole’s lab at the University of 
Louisville (see method of preparation by Yong et al.29).  The solution was stirred 
overnight, then purified via magnetic separation to give gold nanoseed-coated iron oxide 
NPs (Fe@nAu).   
 
Figure 2.4.  STEM Image of Fe@APTES NPs 
(light gray) decorated with gold nanoseeds (bright 
spots) to form Fe@nAu NPs. 
 
 
High-resolution transmission electron microscopy (HR-TEM) and scanning 
transmission electron microscopy (STEM) imaging was performed on Fe@nAu NPs by 
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Dr. Jacek Jasinski.  As seen in Figure 2.4, the Fe@APTES core is a lighter gray, and the 
gold nanoseeds are bright spots.  Each image showed aggregation, but this is common 
when nanoparticles are dried and concentrated for imaging.  Based on the HR-TEM 
images, the average size of the iron oxide NPs was 10 ± 3 nm.  In addition to imaging, 
energy-dispersive X-ray spectroscopy (EDAX) was performed on a gold-seeded iron 
oxide sample.  This allowed precise analysis of the chemical composition of the sample, 
which gave efficacy of coating.  However, there was inconsistency in the coating.  Dr. 
Jasinski provided EDAX readings for 3 different samples, and examined different regions 
within each sample.  As seen in Figure 2.5, iron oxide is observed for regions 1 and 2, but 
only region 1 showed characteristic gold signals.  The inconsistent coating is seen not 
only in multiple areas of the same sample, but also between different samples.  This is 
troublesome because we expected gold nanoseeds to cover the iron oxide core in its 
entirety.  Apparently only portions of the iron oxide core became coated with the gold 
nanoseeds.  Despite this, we continued with the Fe@nAu, hoping the partial gold 
nanoseed coverage would still provide enough nucleation sites to form the gold shell. 
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Figure 2.5.  EDAX of Fe@nAu, showing clear peaks for both iron oxide and gold 
in region 1 (left) but only iron oxide in region 2 (right).  Cu seen in both samples is 
from the grid used for analysis. 
 
Many researchers have reported gold shell formation after gold nanoseed 
attachment (i.e., nucleation).  Procedures utilize chloroauric acid with various reducing 
agents to form the gold shell.  Fe@nAu NPs were suspended in H2O containing HAuCl4, 
followed by addition of reducing agent.  We examined several procedures that utilized 
sodium borohydride,30 ascorbic acid,18 glucose,31 and sodium citrate.32  The product 
obtained by each method was characterized via UV-Vis, dynamic light scattering (DLS), 
and ζ-potential.  UV-Vis allows the detection or absence of a surface plasmon resonance 
(SPR) that is commonly seen with GNPs or a gold shell.  The SPR peak is due to the 
interaction of light with free surface electrons, which in turn oscillate. The electrons can 
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release their energy in the form of heat or light.  Colloidal GNPs give a characteristic 
optical absorption peak around 520 nm.33  DLS measures the hydrodynamic radius of the 
sample, and ζ-potential gives the charge of the NPs in a solution of water.  Results are 
seen in Table 2.1.   
 
Reduction method SPR band DLS (nm) ζ-potential (mV) 
Ascorbic acid None observed 2500 -6.0 
Sodium citrate None observed 3000 -42.0 
Glucose None observed 700, 200 +32.2 
Sodium borohydride None observed 2400 -15.7 
Table 2.1.  Analysis for synthesis of Fe@Au NPs via hydrophilic methods.  All samples 
were measured in 1 mL H2O at a concentration of 0.2 mM. 
 
Unfortunately, none showed a characteristic SPR band representative of gold 
coating. The lack of SPR peaks in any of the samples was disconcerting, and the 
hydrodynamic diameters were far too large to be considered useful.  The ζ-potentials are 
relatively good.  Because ζ-potential is a measure of the surface charge of the NPs, it is 
best of the observed number is largely negative or largely positive.  This ensures 
repulsion between NPs, discouraging aggregation.  Despite the good ζ-potential, the 
excessive hydrodynamic radii made it clear that this hydrophilic method approach was 
problematic.  As mentioned previously, four common hydrophilic methods for gold 
coating were attempted, and each method used freshly made Fe@nAu NPs.  Each method 
was performed only once, but the focus of this thesis work was to expand the use of a 
thermally labile linker to Fe@Au NPs for drug delivery.  In order to perform the 
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necessary experiments, a reproducible method for Fe@Au NPs was necessary.  Thus, 
instead of focusing on attempts to make the hydrophilic method work, we pursued a new 
method needed for Fe@Au NP synthesis. 
While attempting to coat iron oxide with gold via gold nanoseed nucleation and 
reduction, we explored the possibility of capping the dithiocarbamate with methyl to 
produce stable xanthate functionality that could be analyzed prior to gold nanoseed 
capping.  Mattingly et al.26 previously attempted methyl capping of xanthate-coated iron 
oxide NPs with little success.  Despite the failure to do so, a revised attempt to form 
dithiocarbamates followed by methyl capping yielded success.  We followed the previous 
procedure for gold nanoseed capture, but added excess methyl iodide rather than gold 
nanoseeds.  Characteristic stretching of the C–N bond of NCS2Me at 1336 cm-1 and 
asymmetric stretching of CS2 at 960 cm-1 provided evidence for methyl dithiocarbamate 
formation.34  Whereas these results were promising, we did not pursue this approach 
further due to success in ongoing accompanying work that led to our goal. 
  
2.3. CORE-SHELL IRON OXIDE-GOLD NANOPARTICLES 
After failing to prepare Fe@Au NPs via a hydrophilic method, we chose to 
attempt synthesis via the thermal decomposition method to yield hydrophobic Fe@Au 
NPs.  First, we synthesized oleyl amine-coated iron oxide NPs via a modified method 
developed by Park et al.35  Briefly, we heated a biphasic water-ethanol/toluene solution 
of iron (II) and iron (III) salts, as well as sodium oleate, at 75 °C for 4 hours to give 
oleate-coated iron oxide NPs.  The NPs were pelleted from excess reagents via 
centrifugation. HR-TEM, EDAX, and superconducting quantum interference device 
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Figure 2.6.  Characterization of iron oxide NPs.  a. HR-TEM image shows uniformly 
sized NPs.  b. SQUID analysis with field cooling (blue) and zero-field cooling (red); right 
shows magnetic saturation and left shows blocking temperature determination.  c. EDAX 
analysis to show characteristic iron and oxygen peaks; Cu seen in the sample is from the 
grid used for analysis. 
 
HR-TEM revealed an average diameter of 5 ± 1 nm with good monodispersity.  
EDAX gave characteristic peaks for iron oxide.  The Cu peaks are due to the copper grid 
used for analysis.  SQUID measurements showed a magnetic saturation of 0.3 emu/g with 
a narrow hysteresis loop at room temperature.  This indicated superparamagnetic NPs 
because a hysteresis loop should not be detected above the blocking temperature, in this 
case 27 °C.18 
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We then modified a synthesis procedure by Wang et al.23 to coat our newly 
formed NPs with gold.  Briefly, we combined iron oxide NPs with gold (III) acetate, oleic 
acid, oleyl amine, and 1,2-tetradecanediol in phenyl ether under nitrogen at room 
temperature.  This solution was heated to 185 ± 5 °C for 90 minutes.  After cooling to rt, 
the NPs were pelleted via centrifugation.  This procedure allowed for removal of excess 
oleyl amine as well as any gold NPs formed during the synthesis.  STEM, EDAX, UV-








Figure 2.7.  Fe@Au NP Characterization.  STEM image of Fe@Au NPs showing good 
monodispersity of Fe@Au NPs. Top right insert shows size of NP using STEM software.  




Figure 2.8.  Fe@Au NP Characterization.  a. UV-Vis reading that shows characteristic 
SPR absorption around 540 nm.  b. EDAX analysis to show characteristic iron, oxygen, 
and gold peaks; C seen in the sample is from the grid used for analysis. 
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Figure 2.9.  Fe@Au NP Characterization, SQUID analysis.  a. Field loops up to 7 T at 
1.9 K and 300 K.  b. Field-cooled (blue) and zero-field-cooled (red) measurements 
showing temperature dependence of magnetization under 10 mT. 
 
STEM in Figure 2.7 revealed an average NP diameter of 7 ± 3 nm with relatively 
good monodispersity, consistent with literature values.23  EDAX showed characteristic 
peaks for both iron oxide and gold based on literature.24  UV-Vis analysis (Figure 2.8) 
showed a characteristic SPR around 530 nm, consistent with literature values.23,24  
SQUID measurements (Figure 2.9) showed a magnetic saturation of 6 emu/g with a 
narrow hysteresis loop at room temperature.  These results confirm the presence of 
Fe@Au NPs, and we used this material in our subsequent experiments. 
 
2.4. DUAL NANOPARTICLE SYSTEM 
 For reasons that will become clear in a later chapter, we also synthesized a dual 
NP system.  As the name implies, the dual NP system consists of 2 different types of 
NPs: gold NPs for attachment of thiol based moieties, such as our linker, and iron oxide 
NPs for generation of local hyperthermia. 
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Because the thermal decomposition approach worked to prepare Fe@Au NPs, we 
chose a similar procedure sans the iron oxide core to give hydrophobic gold NPs (GNPs).  
de la Presa et al.36 formed GNPs by reducing gold (III) acetate with oleylamine in phenyl 
ether, oleic acid, and 1,2-tetradecanediol at elevated temperatures, which is the synthesis 
we chose to follow.  The resultant GNPs were characterized via DLS and SEM.  DLS 
revealed a hydrodynamic diameter of 224.3 ± 11.2 nm, whereas SEM revealed 5 ± 3.7 
nm (Figure 2.10). 
 
Figure 2.10.  GNP characterization.  SEM image that shows monodispersed GNPs 
(bright spots) with minor aggregation (large bright spots).  GNPs have an average 
diameter of 5 ± 3.7 nm. 
 
 The second portion of our dual NP system is the iron oxide NPs.  As previously 
discussed, iron oxide NPs should be coated to avoid aggregation and prevent oxidation.  
Instead of using a metallic coating as done previously, we chose to make our iron oxide 
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NPs water-soluble by attaching polyethylene glycol (PEG).  This procedure forms a 
ferrofluid, which is a colloidal suspension of surfactant coated magnetic nanoparticles.  
We followed a procedure from García-Jimeno and Estelrich37 that combined PEG 2000 
with iron (II) and iron (III) salts at slightly elevated temperatures.  This was followed by 
addition of ammonium hydroxide to form water-soluble iron oxide NPs (MNPs), which 
were washed repeatedly with water to remove excess PEG 2000.  Characterizations 
included ζ–potential, DLS and SEM.  ζ–potential showed a surface charge of -22.4 ± 2.02 
mV.  DLS showed a hydrodynamic diameter of 716.2 ± 74.3 nm, whereas SEM gave a 





Figure 2.11.  MNP characterization.  SEM image that 
shows good monodispersity (average diameter 50 ± 16 




NP preparation is well described in the literature, yet the process of coating iron 
oxide NPs in a reproducible manner so as to exclude GNP formation is a major challenge. 
Despite following literature procedures, we did not enjoy success in making Fe@Au NPs 
via a gold seeding method, which led us to use a thermal decomposition method.  The 
characterizations showed data that was consistent with literature for Fe@Au NP 
synthesis.  HR-TEM images showed iron oxide cores around 5 nm, and STEM images 
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showed monodispersed, well-defined NPs around 7 nm.  These diameters matched quite 
well with the diameters of the procedure we followed by Wang et al.23  The Fe@Au NPs 
had a characteristic SPR peak for gold, and EDAX readings showing both iron oxide and 







3.2. AMINE LINKER 




We selected a linker for the Fe@Au NP delivery system based on previous work 
done in our lab.  Knipp et al.1 designed, synthesized, and attached a linker to iron oxide 
NPs for the same purpose, namely to respond to an external stimulus (AMF-generated 
local hyperthermia) so that intramolecular cyclization of the linker releases a payload 
(Scheme 3.1).  The initial linker had 3 components: a terminal attachment point to load 
onto a NP surface, a reactive portion that consisted of a nucleophilic amine (blue) and an 
electrophilic carbonyl moiety (red), and a payload (green).   
 
Scheme 3.1.  Thermally responsive linker that 
undergoes intramolecular cyclization upon exposure to 
AMF to release a payload; blue = nucleophilic element 
(amine), red = carbonyl moiety, green = payload  
 
Knipp et al.2 first explored different parameters for optimal linker design prior to loading 
onto a surface (Figure 3.1).  An allyl moiety was chosen as the surrogate for the 
attachment portion because it could easily be modified when needed yet remained inert 
during evaluation of the cyclization parameters.  The reactive portion consisted of a 
nucleophlic amine and various electrophilic carbonyls, including ester (1), carbonate (2), 
carbamate (3), and amide (4).  In addition, the carbon chain length was varied between 
the nucleophilic amine and the electrophilic carbonyl to assess the influence of ring size 
formation on exposure to heat.  The payload used for the studies was anthracene, which is 





Figure 3.1.  Cyclization precursors (R = 2-(9-
anthracenyl)ethyl).  Ring size after intramolecular 
cyclization given in parentheses.  Adapted with 
permission from Tetrahedron 2014, 70, 3422-3429.  
Copyright 2014 Elsevier. 
 
After synthesis, each linker was incubated at 55 °C in methanol for 24 hours.  Aliquots 
were taken at various times for analysis via HPLC to determine percent release.  Ester 1.1 
cyclized most readily, with nearly complete release of the anthracene alcohol group after 
incubation for 24 hours. Thus, this linker design was chosen for application in a carbonyl 
capture demonstration using a poly(dimethylsiloxane) (PDMS) microchannel.  The 
attachment portion was modified to incorporate a triethoxysilane for covalent attachment 
to the microchannel.  The anthracene payload was replaced with an aminooxy moiety 
capable of reacting with carbonyl analytes.  To test the applicability of the system on a 
surface, the siloxane-linker was attached to the microchannel, and then incubated with an 
aqueous soluble fluorophore, fluorecin isothiocyanate (FITC), which was modified with a 

















1.1: n = 1 (5-ring)
1.2: n = 2 (6-ring)
1.3: n = 3 (7-ring )
2.1: n = 1 (5-ring)
2.2: n = 2 (6-ring)
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microchannel was incubated at 60 °C for 30 minutes and nearly complete release of the 
fluorophore was observed. 
With this success, Knipp et al.1 used the aforementioned linker design for 
attachment to iron oxide NPs once again using siloxane methodology, followed by AMF 
exposure to induce local hyperthermia and intramolecular cyclization.  Ester 1.3 (Figure 
3.1) was the linker of choice because it was resistant to cyclization until heated (i.e., 
exposure to local hyperthermia).  As previously discovered by Riedinger et al.,4 iron 
oxide NPs exposed to an AMF provide enough thermal energy for azo bond cleavage, so 
Knipp hypothesized the same energy could drive the intramolecular cyclization.  Because 
the temperature of the NP surface increases first, followed by the change in temperature 
of the bulk solution,5 the area immediately near the NP is much hotter than the bulk 
solution.  Anthracene was used as the payload for its ease of detection using a 
fluorometer in a 2:1 water:acetonitrile solution.  After 30 minutes of AMF exposure, a 
large amount of payload was detected in the supernatant.  Unfortunately, release from the 
NP system without exposure to AMF was seen.  The premature release was presumably 
caused by ester hydrolysis facilitated by iron oxide acting as a Lewis acid.  To mask the 
oxide surface, the use of a silica shell, which reduced the Lewis acidity of the NPs, was 
examined.  The gem-dimethyl carbonate 5 (Figure 3.1) was chosen as the linker for the 
silica-coated iron oxide NP studies because of its greater stability toward hydrolysis and 




Figure 3.2.  Nucleophilic linker attached to silica-coated iron 
oxide NPs (Fe@SiO2). 
 
After the linker was attached to the silica-coated iron oxide NPs, both the Boc-protected 
amine 6 and free amine 7 (Figure 3.2) NPs were exposed to an AMF.  Release was 
observed for 6, which was unexpected because the Boc protecting group makes the amine 
less nucleophilic.  More importantly, the Boc-protected amine is not able to cyclize 
because cyclization would result in a quaternary amine, which is highly unlikely.  For this 
reason, a modified linker that lacked an amine and used a robust N-methyl carbamate 
moiety was explored.  Stronger carbamate functionality would reduce the amount of 
undesired payload release but would release under forcing conditions when local 
hyperthermia was generated upon exposure to AMF.  Instead of relying on intramolecular 
cyclization, the carbamate linker cleaved via pure hydrolysis.  Almost 70% payload 
release was observed after 8 5-minute pulses at 500 A, while less than 10% payload 
release was observed at 37 °C.  Knipp et al. concluded that the silica shell provided 
sufficient hydrogen bonding for accelerated hydrolysis and/or Boc-deprotection of the 
carbonate, as well as accelerated hydrolysis of the carbamate.   
 
3.2. AMINE LINKER 
 This thesis work aims to apply the intramolecular cyclization strategy described 









6: R = C(O)Ot-Bu




drug delivery, including controlled thickness of deposition onto an iron oxide core,6 
covalent attachment of drugs or antibodies,7 and a variety of ways to coat the iron oxide 
core with silica.8  While the silica shell is important to increase functionalization of the 
iron oxide core, bare silica NPs are reactive both in vitro and in vivo, i.e. their silanol 
group is negatively charged at physiological pH (~7.4) and interacts with red blood cells, 
causing hemolysis.7, 9   Even after coating the silica shell, it was still reactive, as 
demonstrated by Knipp et al. with ester and carbonate hydrolysis.  We sought to use a 
gold shell because gold is bioinert10 and is functionalized easily to form covalent bonds 
with thiols.11  We planned our studies to use a mono-thiol because we felt in this case a 
di- or tri-thiol was not necessary.  The 7-membered ring formation was used because of 
its stability at physiological temperatures with response to thermal stimuli at relatively 
high temperatures.  The payload portion of the linker utilized the aminooxy moiety for 
facile attachment of fluorescent carbonyl containing compounds seen in Figure 3.3. 













with FL prior to 
loading onto NPs 
4 steps 7 steps 10 steps 11 steps 
Carbonyl 
functionality Ester Carbonate Carbamate Carbonate 
Ring size 5 7 Amine-free 7 






















Table 3.1.  Summary of improvements relative to Knipp et al.1 
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Figure 3.3.  Fluorophores used as payloads in the present study.  a. Aminooxy of 
amine-based linker reacts quickly and irreversibly with carbonyl-containing 








































Initially, boron-dipyrromethene (BODIPY) was the fluorophore used per 
recommendation of collaborators.   BODIPY is often used in biochemistry for 
conjugation of nucleotides, amino acids, and other low molecular weight ligands.12  It 
was used in early studies because of its superior fluorescence that spans the visible 
spectrum, depending on the modifications.  BODIPY was modified with 
aminoacetaldehyde to yield a carbonyl containing BODIPY-CHO (Figure 3.3a).  
Ultimately, we found little success using this fluorophore because it was insoluble in 
water, despite use of 2:1 water:acetonitrile as well as derivatization of the fluorophore to 
aid in solubility.  We also examined the anthracene fluorophore from the work of Knipp 
et al. in initial proof of concept studies.  Finally, water-soluble molecules were used later 
in our studies, including lissamine rhodamine B (LRB), and fluorescin isothiocyanate 
(FITC).  All fluorophores were attached to the protected linker system (LS) via the click 
oximation reaction depicted in Figure 3.3a.  Lissamine rhodamine B combines the core of 
rhodamine with the sulfonyl groups of lissamine, which can be used for functionalization.  
In our case, a terminal sulfonyl chloride was used, and, following a procedure by Park 
and Yousaf,13 1,4-dioxa-8-azaspiro[4.5]decane was attached followed by stirring with 
acid to yield LRB-CHO (Figure 3.3b).  Unfortunately, we had little success with LRB, 
despite following the literature procedure carefully.  Instead, a derivatized FITC was 
used, which was synthesized previously in our lab.  FITC itself does not contain a 
carbonyl to react with our linker, so it was modified with a short chain that contained a 
terminal amine, which reacted with the isothiocyanate, as well as a terminal acetal, which 




Scheme 3.2.  FITC-CHO synthesis.  Step 1: 4-aminobutyraldehyde diethyl acetal reacts 
at the carbon of the isothiocyanate to install masked carbonyl.  Step 2: Acetal hydrolysis 

























89% yield over 2 steps
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Figure 3.4.  1H NMR spectrum of FITC-CHO in CD3OD.  The characteristic aldehyde 
proton is not evident around 9 ppm. Instead, FITC-CHO reacted with CD3OD to form a 













Scheme 3.3.  Synthesis of protected LS1 15 a. TBSCl, Et3N, CH2Cl2, 0 °C; b. MsCl, 
Et3N, CH2Cl2, 0 °C; c. Phthalimide, K2CO3, DMSO, 75 °C; d. Hydrazine monohydrate, 
CH2Cl2:EtOH, 0 °C; e. MeCN, 55 0 °C, 43% over 5 steps; f. Boc2O, Et3N, CH2Cl2, 0 °C; 
g. TBAF, THF, 0 °C, 98% over 2 steps; h. 1,1’-carbonyldiimidazole, (i-Pr)2NEt, CH2Cl2, 
0 °C; i. N-(2-hydroxyethyl)phthalimide, DBU, MeCN, rt, 51% over 2 steps; j. N2H4•H2O, 
CH2Cl2, 0 °C, 99%; Tr = CPh3, Boc = C(O)Ot-Bu, TBS = SiMe2t-Bu 
 
 The synthesis of the amine linker, protected LS1, is outlined in Scheme 3.3.  Each 
product was characterized by 1H NMR, 13C NMR, and IR, with key intermediates 
characterized by HRMS.  To install the amine moiety, commercially available 1,4-
butanediol 10 was mono-TBS protected and followed by mesylation using standard 
protocols.  Reaction with phthalimide under Gabriel reaction conditions followed by 
hydrazinolysis gave primary amine 11.  Initial syntheses were done on the milligram 
scale but after optimization, the reactions were scaled up and performed on the gram 
scale (e.g. Step a in Scheme 3.4 yielded 4.52 g of a monoprotected diol).  Confirmation 






















(Scheme 3.4, step c) gives characteristic 1H NMR peaks in the aromatic region, but these 
signals are no longer evident in amine 11 (Figure 3.5).a  13C NMR shows peaks in the 
aromatic region as well as the carbonyl carbon signal, but are no longer present after 
hydrazinolysis (Figure 3.6).  IR analysis shows a strong characteristic C=O stretch at 
1707 cm-1 from the phthalimide group but is absent in 11 (Figure 3.7). 
 
 
Figure 3.5.  1H NMR of TBS-protected phthalimide (top) and amine 11 (bottom).  
Aromatic peaks indicative of phthalimide (blue box).  Phthalimide protons 
zoomed in (top) to show doublet of doublet.  aSynthesis of amine 11 has been 












Figure 3.6.  13C NMR comparison of TBS-protected phthalimide (top) and 11 (bottom). 
Aromatic  peaks (120-140 ppm) and carbonyl peak at 168 ppm indicative of phthalimide.   
 
 
Figure 3.7.  IR spectrum of TBS-protected phthalimide (black) with 
























Commercially available 1,3-dibromopropane was reacted with triphenylmethanethiol to 
give the tritylprotected-thiol bromide 3.  Bromide 12 was reacted with 11 then purified 
via column chromatography to give the secondary amine 13.  After purification, the yield 
after 5 steps was 43%.  Purified amine 13 was Boc protected, followed by deprotection of 
the TBS group using fluoride-mediated desilylation.  The purified product was reacted 
with carbonyl diimidizole to give 14.  Characterization using 1H NMR of crude 14 
showed a downfield shift in alpha protons after transformation from a hydroxyl to an acyl 
imidazole (Figure 3.8, proton a, c).  In addition, the hydroxyl proton disappears while the 
acyl imidazole protons are seen in the aromatic region (Figure 3.8, proton b, d).  The 
crude acyl imidazole was reacted with a previously synthesized phthalimide alcohol,14 
followed by hydrazinolysis to reveal aminooxy 15.  At this point, any molecule with a 
carbonyl could be attached for delivery using this system.  Characterization using 1H 
NMR of crude 15 showed protons of the aminooxy as a broad singlet around 5.5 ppm in 
addition to distinction of the ethylene protons a and b (Figure 3.9).  This was used for 
attachment of either anthracene aldehyde or FITC-CHO, followed by trityl deprotection15 
to reveal the thiol for attachment to Fe@Au NPs. 
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Figure 3.8.  1H NMR spectra of alcohol (top) and acyl imidazole 14 (bottom).  Each 























Figure 3.9.  1H NMR spectra of phthalimide (top) and aminooxy 15 (bottom).  Each 
sample was dissolved in CDCl3 with TMS and spectra were taken on a 400 MHz NMR 
machine. 
 
3.3. AMINE-FREE LINKER 
 In anticipation of demonstrating that the mechanism of payload release will 
proceed via intramolecular cyclization, we pursued synthesis of a control linker system 
that lacked the amine moiety while retaining all other aspects.  Without an amine moiety 





























Scheme 3.4.  Synthesis of protected LS2 18 a. Triphenylmethanethiol, K2CO3, 
EtOH:H2O, 90 °C; b. 1,1’-carbonyldiimidazole, (i-Pr)2NEt, CH2Cl2, 0 °C; c. N-
(2-hydroxyethyl)phthalimide, DBU, MeCN, rt, 54% over 3 steps; d. N2H4•H2O, 
CH2Cl2, 0 °C, 98%. 
 
The synthesis for the amine-free linker is outlined in Scheme 3.4.  Each product was 
characterized by 1H NMR, 13C NMR, and IR, with key intermediates were characterized 
by HRMS.  Commercially available 6-bromo-1-hexanol 16 was reacted with 
triphenylmethanethiol to give trityl protected thio-alcohol as described in the amine-
based linker, followed by reaction with 1,1’-carbonyldiimidazole to give the acyl 
imidazole intermediate 17. Characterization of both the alcohol and acyl imidazole 
products via 1H NMR is seen in Figure 3.10 and via IR is seen in Figure 3.11.  As seen 
with LS1, the proton from the alcohol disappears and a downfield shift is seen in the 
alpha protons.  In addition, the characteristic OH stretch is seen for the alcohol and the 
C=O stretch is seen with the acyl imidazole.  17 was reacted with a previously 
synthesized phthalimide alcohol14 and purified via column chromatography.  The yield 
over 3 steps after purification was 54%.  The phthalimide was cleaved via hydrazinolysis 
to give aminooxy 18.  Characterization using 1H NMR of crude 18 showed protons of the 
aminooxy as a broad singlet around 5.5 ppm in addition to distinction of the ethylene 












aldehyde or FITC-CHO, followed by trityl deprotection12 to reveal the thiol for 
attachment to Fe@Au NPs.  Spectral comparison of protected LS1 and protected LS2 is 
seen in Figure 3.13. 
 
Figure 3.10.  1H NMR spectra of alcohol (top) and acyl imidazole 17 (bottom).  Each 



















Figure 3.11.  IR spectrum of alcohol (black) with characteristic OH stretch 
at 3362 cm-1 that is absent in acyl imidazole 17 (red), but instead has a 




Figure 3.12.  1H NMR spectra of phthalimide (top) and aminooxy 18 (bottom).  Each 


















































































Our goal was to prepare a linker system that: 
TASK 1: could be readily “loaded” with a carbonyl substrate (e.g, FL or drug) 
TASK 2: could be readily attached to GNPs 
TASK 3: is resistant to non-triggered hydrolysis 
TASK 4: responds to local hyperthermia to release attached carbonyl substrate 
 
The following features within the linker system address each task: 
 
SOLUTION 1: -ONH2 methodology allows for facile “click” attachment of carbonyl 
substrates. 
SOLUTION 2: -SH functionality allows for strong binding to surface of GNPs as well as 
Au shells. 
SOLUTION 3: Carbonate functionality is more resistant to hydrolysis than ester 
functionality.  In addition, 7-membered ring formation (slow) was selected to discourage 
unassisted intramolecular cyclization. 
SOLUTION 4: The pendant amine reacts only when local heat available to power a 7-
ring intramolecular cyclization, which results in substrate cleavage. 
  
As mentioned previously, researchers explored the idea of thermally responsive linkers 
with either azo or retro-DA functionality.  These applications were attached to iron oxide 
NPs and were successful in externally triggered payload release.  The use of linkers that 







reactions) is limited, so we sought to extend AMF technology to a more readily applied 
release mechanism of intramolecular cyclization in an effort to expand this type of drug 
delivery system.  Use of a gold shell allows a quick and facile covalent bond between the 
gold and the thiol functionality without the use of heat or vacuum as seen previously with 
a silica shell.  In addition, gold is inert, meaning it would not have interaction with the 
linker other than initial attachment so undesired payload release would be minimal.  For 
these reasons, modifications were made for attachment to a gold shell and for 




ASSEMBLY AND TESTING OF Fe@Au NP SYSTEMS 
________________________________________________________________________ 
4.1. INTRODUCTION 
4.2. INITIAL STUDIES – ANTHRACENE 
4.3. WATER SOLUBLE STUDIES – FITC 




 Our amine linker attached to Fe@Au NPs is designed to cyclize in response to 
local hyperthermia that can be generated upon exposure to an alternating magnetic field 
(AMF).  AMF is an effective method to create local hyperthermia when using magnetic 
NPs, as described in Chapter 1.  The amount of heat generated by the NPs in watts per 
gram of iron (W/gFe) is denoted as the specific absorption rate (SAR).  This can vary 
when the machine is “on” because it is not only based on NP morphology, but is also 
determined by the settings of the instrument, mainly power (W), current frequency (Hz), 
and current amplitude (A).  The current is the flow of electrons, and the electron flow acts 
as a wave with variances in frequency and amplitude, as illustrated in Figure 4.1. 
 
 
Figure 4.1.  Electrons behave as waves in a current.  The frequency is the number of 
cycles completed per unit time (blue).  The amplitude is the maximum height of the wave 
from its start point (red).  An alternating current has positive voltage (above gray line) 
and negative voltage (below gray line). 
 
 
An electrical current running tough coils generates a magnetic field, as seen in 
Figure 4.2.    In the case of an AMF, the current alternates direction based on the 







Figure 4.2.  Magnetic field generation. When current flows 
through the coil (black), a magnetic field (green) is generated 
in the direction.  In this example, the current flows in through 
the bottom of the coil and out through the top of the coil, and 
the magnetic field direction is indicated by the arrows. 
 
Heat generation, or SAR, is dependent partially on the magnetic field strength (kA 
m-1) and partially on frequency (Hz).  Guardia et al.i explored both magnetic field 
strength and frequency as it relates to SAR.   For magnetic nanocubes, SAR varied 
linearly with the square of the strength of the magnetic field (Figure 4.3a), and SAR 
varied linearly with the frequency of the current (Figure 4.3b).  In terms of AMF settings, 
this means a larger amplitude and/or frequency of current leads to larger heat dissipation, 




Figure 4.3.  a. At constant magnetic field strength (solid: 14 kAm-
1, open: 18 kAm-1), SAR (W/gFe) readings correlate in a direct 
linear fashion with frequency (kHz).  b. At constant frequency 
(700 kHz), SAR (W/gFe) readings correlate in a direct linear 
fashion with the square of the magnetic field strength (kAm-1).  
Adapted with permission from ACS Nano 2012, 6, 3080-3091.  
Copyright 2012 American Chemical Society. 
 
 Generating local hyperthermia for cancer therapy is an area of great interest.  
However, setting AMF parameters too high can lead to thermal ablation rather than local 
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hyperthermia, so settings must be carefully regulated for in vivo treatment.  In 1984, 
Atkinson et al.ii implanted thermoseeds in healthy volunteers and concluded tolerance up 
to 35.8 Aturns m-1 at a frequency of 13.56 MHz for 1 hour.  Safety limits from this study 
led to the “Brezovich criterion”, an equation where the product of the amplitude and 
frequency should not exceed 4.5 x 108 Am-1s-1.iii  Various in vivo testings have shown 
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Table 4.1.  Examples of in vivo thermotherapy that adhere to the Brezovich criterion.  
Light gray portion represents NPs with thermally labile linkers, and settings used for the 
present thesis work are in blue.  See Chapter 4, reference 4, for references to each work. 
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 Recent payload release studies via a thermally labile linker show relatively similar 
AMF settings (Table 4.1, light gray).  Adherence to the Brezovich criterion is crucial for 
drug delivery that will rely on AMF exposure.  Thus, we chose our AMF settings to be 
similar to the recent given examples in literature (Table 4.1, blue).  
 
4.2. INITIAL STUDIES – ANTHRACENE 
 The setup of AMF for the following studies is seen in Figure 4.4.  The machine is 
an Ambrell® EasyHeat Induction Heating System 10.0 kW with a 5-turn coil for AMF 
exposure.  The machine settings, such as current amperage and duration of AMF 
exposure, can be adjusted, but the frequency is set at 203 kHz (Figure 4.4a, red box).  The 
bulk solution temperature is monitored using Neoptix NeoLink software, and the 
computer is connected to the temperature monitor (Figure 4.4a, green box) with a fiber 
optic probe (Figure 4.4a, yellow).  The sample in an Eppendorf tube, surrounded by 
ceramic paper (Ambrell) to prevent heat from the coils to influence the bulk temperature, 
is placed on a plastic box at the center of the coils (Figure 4.4a, orange box; Figure 4.4b). 																																																									
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Figure 4.4.  AMF machine setup.  a. Overall view.  In the red box, settings such as 
current amperage and duration could be adjusted.  The frequency for this machine was set 
to 203 kHz and could not be adjusted.  In the green box, a computer uses Neoptix 
NeoLink software and is connected to a temperature monitor (grey box) with a fiber optic 
probe (yellow).  The orange box contains the sample with the probe to monitor bulk 
solution temperature placed in the middle of the coils.  b. A closer view of the orange box 
from a shows the sample in an Eppendorf tube surrounded by ceramic paper (Ambrell®, 
0.06” thick) to prevent heat transfer from coils.  Inset shows aerial view of sample setup. 
   
Prior to loading LS1 (Scheme 4.1, 20) on Fe@Au NPs, we attached a fluorophore 
via the aminooxy functionality.  For initial studies, an anthracene-aldehyde 8 was used, as 
previously studied in our lab.i  Fluorophore 8 was loaded on protected LS1 15 to give 
protected LS1-anthracene 19, which was characterized via 1H NMR, 13C NMR, and IR.  





Figure 4.5.  1H NMR spectrum of protected LS1-anthracene 19.  The chemical shift 
differences between the E and Z isomer are seen in proton a and proton b. 
 
Because the payload release weight is identical for both isomers, the geometry of the 
isomer is trivial.  The trityl and Boc protecting groups were simultaneously removed 
following a literature procedure to give LS1-anthracene 20.i  Briefly, 19 was dissolved in 
1:1 TFA:CH2Cl2 at 0 °C, followed by addition of Et3SiH.  The importance of Et3SiH for 
























Scheme 4.1.  Mechanism of trityl deprotection. 
 
After TFA protonates the sulfur (Step 1), SN1 chemistry occurs to form a thiol and a 
tertiary carbocation (Step 2).  The hydride of Et3SiH reduces the carbocation to give 
triphenylmethane and triethylsilyl trifluoroacetate (Step 3).  The solution was stirred for 
30 minutes, and upon completion was concentrated in vacuo to give 20 and was used 
without further purification.  20 was not characterized via NMR to prevent dithiol 
formation prior to loading onto NPs, but a clear decrease in Rf value indicated 
completion.  After concentration in vacuo, 20 was redispersed in CH2Cl2, added dropwise 
to NPs in hexanes, and stirred rapidly for 4 hours.  The ratio of linker to NPs was 0.04 
mmol linker per 1 mg NPs.  This initial loading method was determined our 
collaborators, who also work in the nanoparticle field, Dr. Ralf Schirrmacher and Dr. Jun 





































with EtOH, purified via centrifugation, and dried in vacuo to give Fe@Au@LS1-
anthracene NPs (Scheme 4.1, 21). 
 
Scheme 4.2.  Synthesis of Fe@Au-LS1-anthracene (5).  a. CH2Cl2, rt, 16 
h, 99%; b. Et3SiH, 1:1 TFA:CH2Cl2, 0.5 h; c. CH2Cl2, rt, 16 h. 
 
The loaded NPs then were dispersed in 1 mL of a 2:1 water:acetonitrile in a cuvette, 
followed by exposure to an AMF at 500 A for 15 minutes.  After exposure, the NPs were 
separated via a strong magnet (N52 neodymium 1” magnetic cube, Applied Magnets, 
Texas) and the supernatant was analyzed via matrix assisted laser desorption ionization-
time of flight (MALDI-TOF).  When detecting a peak of interest in MALDI, it is possible 





























+ 39).  Thus, masses for each of these versions were calculated and then inspected during 
analyses.   
 
 
Figure 4.6.  MALDI-TOF spectrum of supernatant obtained from 
Fe@Au@LS1-anthracene experiment after exposure to AMF at 500 A 
for 15 minutes.  The theoretical m/z for the protonated “payload” 
fragment corresponds to the found m/z value of 279.22, confirming 
payload release.  The signal at 242.47 corresponds to a peak from the 
matrix 2,5-DHB. 
   
As seen in Figure 4.6, the signal for the protonated “payload” fragment [22]+ is observed 
at a m/z of 279.22.  This data strongly supports the notion that 22 is released as a result of 
the AMF exposure, but the actual mechanism of cleavage must still be verified.  To 
investigate our intramolecular cyclization hypothesis, we loaded Fe@Au NPs with our 
amine-free linker, LS2-anthracene (24).  The method in which the NPs were reacted with 
the linker thiol was kept the same.  Click-chemistry oximation of anthracene-aldehyde 8 
onto protected LS2 18 delivered protected LS2-anthracene 23.  Protected LS2-anthracene 
23 was characterized via 1H NMR, 13C NMR, and IR.  Trityl deprotection gave LS2-
anthracene 24, which was used without further purification.  24 was not characterized via 
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NMR to prevent dithiol formation prior to loading onto NPs, but a clear decrease in Rf 
value indicated completion.  After concentration in vacuo, 24 was redispersed in CH2Cl2, 
added dropwise to NPs in hexanes, and stirred rapidly for 4 hours.  The ratio of linker to 
NPs was 0.04 mmol linker per 1 mg NPs.  After 4 hours, the NPs were precipitated with 
EtOH, purified via centrifugation, and dried in vacuo to give Fe@Au@LS2-anthracene 
NPs (Scheme 4.2, 25).  The NPs were dispersed in 1 mL of a 2:1 water:acetonitrile 
cuvette, followed by exposure to an AMF at 500 A for 15 minutes.  After exposure, the 
NPs were separated via a strong magnet and the supernatant was analyzed via MALDI-
TOF.  As seen in Figure 4.7, the m/z signal of 279.22 for the protonated “payload” 





Scheme 4.3.  Synthesis of Fe@Au-LS2-anthracene (9).  a. CH2Cl2, rt, 16 



























Figure 4.7.  MALDI-TOF spectrum of supernatant obtained from 
Fe@Au@LS2-anthracene experiment after exposure to AMF at 500 A 
for 15 minutes.  The theoretical m/z of 279.22 for protonated “payload” 
fragment is not seen in the spectrum, nor is the theoretical m/z for the 
sodiated or potassiated “payload” fragment.  This led us to believe a 
payload was not released.  The signal at 205.22 corresponds to a peak 
from the matrix 2,5-DHB. 
 
While this result was what we expected, it is not conclusive (e.g., lack of a signal may be 
due to other factors).  It is possible that, despite following the same preparation, LS2-
anthracene 24 was not loaded onto the Fe@Au NPs as efficiently.  We therefore sought a 
method to chemically cleave the payload from the Fe@Au-LS2-anthracene NPs 25 to 
demonstrate that the system, in fact, did load LS2-anthracene 24, but simply did not 
release it upon exposure to an AMF (Figure 4.9).  To cleave carbonate functionality, 
forcing conditions, such as strong base, are usually required.  Concellón and del Solari 
used 50% w/w aqueous NaOH at room temperature to hydrolyze a chiral carbonate in 
MeOH to afford enantiopure diols.  We tested protected LS2-anthracene 23 prior to trityl 
deprotection and loading onto NPs following this procedure.  Briefly, we added 50% 
aqueous NaOH to protected LS2-anthracene 23 in methanol and monitored the reaction 
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via TLC.  The starting material was not consumed, even after 4 hours.  Despite this, the 
reaction was worked up, and analysis of the crude product via 1H NMR revealed no 
carbonate cleavage.  Subsequent experiments at an elevated temperature (i.e. 70 °C for 8 
hours) did provide evidence for carbonate cleavage via TLC monitoring, but 1H NMR 
analyses were not entirely clear.  We next explored reducing the carbonate using lithium 
aluminum hydride (LAH), a different method used by Concellón and del Solar for 
carbonate cleavage (Figure 4.9). 
 
Scheme 4.4.  Protected LS2-anthracene cleavage using LAH.  Ethylene protons that 
showed signal shift are indicated by a and b. 
 
LAH is a strong reducing agent that reacts with carbonate functionality at room 
temperature (25 °C).7 1H NMR analyses of the reaction of 23 with LAH in THF at room 
temperature for 1 hour showed peak shifts in the signals from the ethylene protons 
between the carbonate and payload (Scheme 4.3), indicative of carbonate cleavage.  This 
led us to testing the linker on Fe@Au@LS2-anthracene 25 to determine whether or not 
the NPs were initially loaded.  After reaction of 25 with LAH at 25 °C for 1 hour, the 
supernatant was analyzed via MALDI.  The protonated payload release m/z was present, 
which confirmed that 24 was indeed loaded onto the NPs.  However, reaction of 25 with 















For cleaner analysis, instead of cleaving the carbonate to prove linker attachment, 
we sought a method to cleave the gold-thiol bond to give the linker system plus payload 
in its entirety (Figure 4.9).  We chose the reducing agent, dithiothreitol (DTT), which is 
used in both gold-thiol bond cleavage as well as in dithiol reduction.ii  Modifying a 
literature procedure initially disclosed by Storhoff et al., iii  we incubated 10 mg of 
Fe@Au@LS2-anthracene 25 with 400 µL of 0.1 M DTT for 2 hours, followed by 
magnetic separation and supernatant analysis. 
 
 
Figure 4.8.  MALDI-TOF spectrum of supernatant obtained from Fe@Au@LS2-
anthracene experiment after incubation with DTT for 2 hours (no AMF application prior).  
The theoretical m/z of 478.15 for potassiated LS2-anthracene corresponds to the found 
m/z value of 478.14, confirming linker loading.  The signal at 411.49 corresponds to a 
peak from the matrix 2,5-DHB. 
 
 
This was done without exposure of the NPs to an AMF prior to DTT cleavage to 
determine if, in fact, 24 was loaded.  MALDI-TOF analysis (Figure 4.8) showed a m/z 
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peak at 478.14, corresponding to the mass of the entire linker 20 plus potassium (m/z = 
478.15).  This data confirmed loading of LS2-anthracene onto the Fe@Au NPs.  The 
previous negative results of payload release from AMF exposure of Fe@Au@LS2-
anthracene, followed by these results confirming LS2-anthracene 24 loading, proved our 
hypothesis.  The mechanism for release was not due to carbonate hydrolysis; rather, 
intramolecular attack of the amine on the carbonate, powered by the local hyperthermia 
after exposure to an AMF, is a reasonable action to expect for release of anthracene 
fragment 22 from LS1 versus LS2, where the attack is not possible. 
 
Figure 4.9.  Cleavage strategies to confirm retention of 
payload in 25.  The first and second strategies to cleave the 
carbonate bond using aq. NaOH and LAH, respectively, 
gave analytically complicated results.  Cleavage of the 
gold-thiol bond using DTT, however, clearly showed the 
linker in its entirety. 
 
4.3. WATER SOLUBLE STUDIES – FITC 
 Knowing that LS1 on Fe@Au NPs responded to AMF exposure, we sought to 
examine the system using aqueous conditions to determine its release profile in 
comparison to LS2.  The amount of LS loaded onto NPs was modified slightly for these 
studies.  Previously synthesized Fe@Au-LS1-anthracene underwent thermogravimetic 









of temperature.  The TGA results are seen in Figure 4.10, with calculations below.  An 
amount of 2.457 mg of Fe@Au-LS1-anthracene was heated from 25 °C to 800 °C over 
30 minutes with a loss of 0.2015 mg (pink).  Using the molecular weight of LS1-
anthracene (468.2 g/mol), the amount of mmol LS1-anthracene lost for 2.457 mg of 
Fe@Au-LS1-anthracene was calculated as 4.3 x 10-4 mmol (Figure 4.10a).  By 
subtracting the amount of LS1-anthracene lost from the total weight, the amount of 
Fe@Au NPs could be calculated (Figure 4.10b).  The amount of mmol LS loaded on each 
mg NP was calculated as 1.9 x 10-4 mmol/mg (Figure 4.10c).  Optimal loading amount of 
linker to NP was to be 100 times excess as determined by consultation with a 
collaborator, who works in the gold nanoparticle field, Mr. Kurtis James of the University 
of Louisville, Kentucky.  A total of 0.02 mmol LS per 1 mg Fe@Au NP was used.  This 
is half that of previous studies (0.04 mmol LS per 1 mg Fe@Au NP), meaning linker was 
not wasted during loading. 
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Figure 4.10.  TGA analysis to determine weight of LS1-anthracene loaded onto Fe@Au 
NPs.  An amount of 2.457 mg Fe@Au-LS1-anthracene lost 0.2015 mg LS1-anthracene.  
The total amount of LS1-anthracene loaded onto 1 mg Fe@Au NPs was calculated as 1.9 
x 10-4 mmol. 
 
Prior to NP loading, LS1 and LS2 required a water-soluble fluorophore, and, as 
mentioned previously, we chose FITC-CHO.  Synthesis of FITC-CHO 9 was described in 
Scheme 3.4.  The procedure for fluorophore loading and attachment to NPs is the same as 
with anthracene aldehyde 8 but with FITC-CHO 9 instead (Scheme 4.4, 4.5).  Briefly, 15 
or 18 was dissolved in 9:1 CH2Cl2:MeOH followed by addition of FITC-CHO to give 
crude protected LS1-FITC 26 or protected LS2-FITC 27.  Characterization of 26 via 1H 
NMR in CDCl3 (Figure 4.11, top) reveals a lack of –ONH2 protons, but the FITC-CHO is 
not seen.  This is because FITC-CHO is not soluble in CDCl3, but when 26 was dissolved 
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in DMSO-d6 (Figure 4.11, bottom), it not only showed the fluorophore attached but also 
showed E and Z isomers as indicated by the blue boxes.  Protecting group removal with 
TFA and Et3SiH revealed LS1-FITC 28 or LS2-FITC 29.  After concentration in vacuo, 
28 or 29 was redispersed in 9:1 CHCl3:MeOH and added to rapidly stirring Fe@Au NPs  
dissolved in CHCl3.  The mixture was allowed to stir overnight and concentrated in vacuo 
to give Fe@Au-LS1-FITC NPs 30 and Fe@Au-LS2-FITC NPs 31. The NPs were washed 
sequentially with EtOH, saturated sodium bicarbonate, and water, pelleting each time via 
centrifugation before the next wash.  Once loaded onto the NPs, Fe@Au-LS1-FITC NPs 
30 were water soluble, but unexpectedly Fe@Au-LS2-FITC NPs 31 were not water-
soluble, as seen in Figure 4.12.  The key difference between the linkers is the secondary 
amine.  We surmise that its ability to hydrogen bond with solvent aids in the water 
solubility of Fe@Au@LS1-FITC NPs 30.  Fortunately, a common ligand to increase NP 
water-solubility is polyethylene glycol (PEG) – the oxygen abundant polymer forms 
hydrogen bonds with water.  For that reason, we pursued incorporating PEG to increase 




Figure 4.11.  1H NMR spectra of 26 in DMSO-d6.  The protons from FITC-CHO are 
indicated in green boxes.  Signals between 9.0 and 10.2 ppm indicate excess FITC-CHO 
in solution.  As seen with the ethylene protons of protected LS1-anthracene 19, E and Z 




Scheme 4.5.  Synthesis of Fe@Au-LS1-FITC (30).  a. 9:1 CHCl3, rt, 16 h, 
































































Scheme 4.6.  Synthesis of Fe@Au-LS2-FITC 31.  a. 9:1 CHCl3, rt, 16 h, 


























































Figure 4.12.  Dispersion of Fe@Au@LS1-FITC NPs 
(left) and Fe@Au@LS2-FITC NPs (right) in 1X PBS 
buffer (pH = 7.4) after sonication.  Fe@Au@LS1-
FITC NPs are well dispersed indicated by the 
homogenous color, but Fe@Au@LS2-FITC NPs 
sediment at bottom of the vial. 
 
For our NPs in particular, we used a PEG (MW 5000) modified with a terminal 
thiol for attachment to our Fe@Au NPs.1  We explored a variety of ratios of linker to 
PEG (Table 4.2) to maximize payload release while maintaining water solubility.  That is, 
the greater amount of LS attached, the greater amount of payload carried for release.  







(LS:PEG) LS1-FITC LS2-FITC 
1:1 Soluble Soluble 
7:3 Soluble Not Soluble 
9:1 Soluble Not Soluble 
10:0 Soluble Not Soluble 
 
Table 4.2.  Ratios of LS:PEG explored.  Each ratio 
used with LS1-FITC was soluble in 1X PBS, 
whereas only 1:1 LS2-FITC:PEG was soluble in 
1X PBS. 
 
Following Carril et al.2 in their coating of Fe@Au NPs, we began with a 1:1 
mixture of mmol linker: mmol PEG-SH.  Preparation of the linker system for NP coating 
remained the same, but prior to its addition, PEG-SH was added to the mixture.  The 
solvent medium changed from CH2Cl2 to CHCl3 to follow a literature prep.10 A 1:1 
mixture of 28 or 29 and PEG-SH was dissolved in 9:1 CHCl3:MeOH and added to 
rapidly stirring Fe@Au NPs dissolved in CHCl3.  The mixture was allowed to stir 
overnight, concentrated in vacuo, redissolved in CHCl3, suspended in EtOH, and purified 
via centrifugation.  After centrifugation, water solubility was evaluated by adding water 
to the NPs followed by sonication.  Both Fe@Au-LS1-FITC-PEG NPs (Figure 4.14a) and 
Fe@Au-LS2-FITC-PEG NPs (Figure 4.14b) were water-soluble, as seen in Figure 4.12.   
We also explored linker:PEG ratios of 7:3, 9:1, and 10:0 for both linker systems (Table 
4.2).  Because Fe@Au@LS1-FITC NPs 30 were water-soluble without the addition of 
PEG, each of the ratios was water-soluble as well, as expected.  Surprisingly, the only 
ratio that was water soluble for LS2-FITC:PEG was 1:1.  Despite long sonication times to 
aid in dispersion, none of the ratios that increased the linker to above 1:1 were water-
soluble.  Thus, we continued our studies with this ratio. 
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Once the NP system was optimized, Fe@Au-LS1-FITC-PEG NPs 30 were 
characterized via UV-vis spectroscopy, ζ-potential, DLS, and SEM.  UV-vis showed a 
characteristic surface plasmon resonance band at 531 nm, indicating the presence of gold.  
The ζ-potential was 12.6 ± 0.212 mV.  This is not surprising because both LS1-FITC and 
PEG are neutral in water.  The DLS reading was 229.5 ± 0 nm, but the particles show 
relatively good monodispersity and have an average diameter of 23 ± 7 nm based on 
SEM imaging (Figure 4.13). 
 
Figure 4.13.  Fe@Au-LS1-FITC-PEG NPs 30 characterization.  SEM image shows 
moderate monodispersity of NPs (bright spots) with some salts from washing (light gray 
spots).   
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Figure 4.14. a. Fe@Au-LS1-FITC NPs 30 and b. Fe@Au-LS2-FITC 
NP 31, with optimal ratio of PEG to LS-FITC as 1:1. 
 
 The release profiles were evaluated for both Fe@Au@LS1-FITC-PEG NPs 30 
and Fe@Au@LS2-FITC-PEG NPs 31.  Prior to the studies, a calibration curve was 
created to determine the amount of payload release, as seen in Figure 4.15.  Though the 
fit is not ideal, this calibration curve incorporates all concentration values seen in the 
following experiment.  The excitation and emission of FITC was chosen as 475 nm and 
525 nm, respectively, based on maximum excitation and emission studies.  These were 
input into the software for single read mode.  FITC has a relatively high fluorescence 
quantum yield, that is “the fraction of the number of quanta absorbed by a molecule that 
are emitted as fluorescence” is near 1.0.3  For this reason, FITC could be detected in the 
picomolar range on the fluorometer.  The settings on the AMF were maintained as in our 



































Figure 4.15.  FITC calibration curve to include concentration 
values 17 pM to 15.63 mM.  Concentrations were established 
through serial dilutions of FITC dissolved in 1X PBS buffer 
followed by fluorescence readings.  Though R2 value is only 
0.977, the large concentration range included the smaller percent 
release from Fe@Au-LS2-FITC-PEG as well as the larger percent 
release from Fe@Au-LS1-FITC-PEG and “100%” after DTT 
incubation. 
 
Our initial studies showed release after only 15 minutes, but we wanted use 
exposure times similar to that of current testing in vivo.  In order to track how much 
payload was released over time, we chose to expose the NPs to four 15-minute AMF 
bursts with fluorescence readings after each burst.  We also chose to pellet the NPs as a 
means to completely remove them from suspension so as not to interfere with the 
readings.  For the studies, 10 mg of Fe@Au-LS-FITC-PEG were placed in an Eppendorf 
tube with 1 mL 1X PBS buffer (pH 7.4) and then sonicated to suspend.   The Eppendorf 
tube was placed at the center of the AMF coil, and a fiber optic temperature sensor was 
placed in the solution to monitor bulk solution temperature.  All data was recorded using 
























kHz), followed by centrifugation at 10K rpm for 5 minutes (Figure 4.16a).  The 
supernatant was removed via pipette, added to a plastic cuvette with 2 mL fresh 1X PBS 
buffer, and analyzed via a fluorometer.  The concentration of cleaved payload was 
calculated based on the calibration curve.  After each reading, the solution that was 
analyzed was added back to the tube containing the NPs and resuspended via sonication 
so that a cumulative measurement could be made.  The total amount of fluorophore 
loaded onto the NPs – 100% release – was measured after the 4th reading by addition of 
400 µL of a 0.1 M solution of DTT, incubation at rt for 2 hours, centrifugation at 10K 
rpm for 5 minutes, addition of the supernatant to the cuvette followed by a final reading 
(Figure 4.16b).  Each percent release was determined relative to the total to establish 
percent released.  The studies via AMF were performed on both Fe@Au-LS1-FITC-PEG 







Figure 4.16.  a. Fe@Au-LS1-FITC-PEG NPs 32 were exposed to AMF for 15 minutes 
then pelleted via centrifugation for fluorescence readings.  This process was repeated a 
total of four times.  After the final reading, the NPs were incubated with DTT for 2 hours 
then pelleted via centrifugation to give “100%” fluorescence reading.  This entire process 
was performed with Fe@Au-LS2-FITC-PEG NPs 33 as well.  b. As exposure time to 
AMF increased, the percent of payload release increased, as indicated by the darker 
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Figure 4.17.  Release profile for Fe@Au-LS1-FITC-PEG NPs 30 (red) 
and Fe@Au-LS2-FITC-PEG NPs 31 (blue) with 10 mg NP system in 1 
mL 1X PBS buffer (pH 7.4).  Percent payload released after 4 15-minute 
bursts of AMF exposure (500A, 203 kHz).  The bar gives average release, 
and the error bars display standard deviation (n = 3). 
 
The release profile for both Fe@Au-LS1-FITC-PEG NPs 30 and Fe@Au-LS2-
FITC-PEG NPs 31 is seen in Figure 4.17.  After the first 15-minute burst, almost 15% of 
the payload for LS1 system was released into solution, followed by reaching a plateau of 
~40% release after the next 3 bursts.  As anticipated, after a total exposure time of 60 
minutes, LS2 showed significantly less release than LS1 with only 10% release after 1 
hour total exposure time.   Starting at room temperature (average temperature of 25 °C), 
the temperature of the bulk solution reached a maximum temperature of 33 °C, 34.3 °C, 
32.5 °C, and 33.3 °C for the 1st through 4th 15-minute exposures, respectively.  The bulk 
temperature of solution with 1X PBS only had a maximum temperature of 32.1 °C after 
15 minutes of exposure to AMF.  Release profiles were also explored at physiological 
temperature (37 °C) as well as 50 °C.  After incubation of 10 mg Fe@Au-LS1-FITC-



















and 8.4 ± 6.4% release was seen, respectively.  These results suggest that bulk solution 
temperature does not play a pivotal role in payload release, rather it is the temperature 
generated at the surface of the NPs that contributes (i.e., actuates intramolecular 
cyclization) to cause payload release.  The high temperature at the surface of the 
nanoparticle is accompanied by a very fast drop in temperature farther from the surface 
(i.e., 0-5 nm vs >5 nm), according to the findings by Riedinger et al.4  
While these results were exciting and showed a new mechanism is operative for 
the first time, the plateau at 40% release perplexed us.  A 100% payload release can be 
expected because the mechanism should not be hindered in some NPs versus others.  We 
postulated that perhaps the addition of the PEG coating was trapping the payload after 
release from the linker.  To explore this possibility, we performed the AMF studies with 
Fe@Au-LS1-FITC-PEG NPs 30 by washing the NPs with 1X PBS buffer.  That is, we 
placed the first supernatant after AMF exposure into an empty cuvette, resuspended the 
NPs in fresh 1X PBS via sonication followed by centrifugation.  The supernatant was 
removed and placed into the cuvette, and this process was repeated once more.  This 
method was performed after each 15-minute exposure to AMF to determine the non-
cumulative amount released after each burst.  After the 4th reading, the NPs were 
incubated with 400 µL 0.1 M DTT for 2 h and washed as just described.  Each release 
profile was calculated based on the calibration curve.  To make the results comparable to 
the previous cumulative results, each concentration after exposure was added to the 
previous results (e.g. concentration reading after 15 minutes was 2.72 pM and 
concentration reading after 30 minutes was 0.93 pM meaning the total release at 30 
minutes was 3.65 pM).  The reading after DTT that represented 100% release added all 
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readings together.  Overall, the percent release was similar to the readings without 
washing.  This disproved our hypothesis of the released fluorophore being trapped within 
the PEG layer.  The plateau observation remains to be explained. 
We next thought to increase the amount of local hyperthermia generated from the 
Fe@Au NPs.  As stated previously, the maximum bulk temperature for each burst was no 
higher than 35 °C, and the bulk temperature of 1X PBS buffer without NPs was 32 °C.  
We thought it possible that the concentration of iron oxide might be too low to produce 
the necessary thermal energy for intramolecular cyclization and payload release.  This 
could be overcome by either decreasing the amount of solvent with the same amount of 
iron oxide or increasing the amount of iron oxide with the same amount of solvent.  We 
chose the latter and explored “spiking in” iron oxide NPs to cause the bulk solution to 
heat to a greater extent, thus triggering more payload release.  Our first attempt involved 
combining 10 mg of Fe@Au-LS1-FITC-PEG NPs 30 in 1 mL 1X PBS buffer with 10 mg 
iron oxide NPs, previously made for the gold nanoseed project.  The cumulative release 
method was reinstated, as the washing method was clearly no better.  Analysis of the 
supernatant showed release percentages similar to what we observed before.  However, 
we noted that in this experiment the Fe3O4 NPs were not water-soluble and thus were not 
adequately suspended in solution.  Rather, the added iron oxide NPs sank to the bottom 
of the Eppendorf tube during AMF treatment, while Fe@Au-LS1-FITC-PEG NPs 30 
remained suspended in solution.  The bulk solution had an average temperature of 39 °C, 
which was higher than the temperature seen with Fe@Au NPs.  Likely, the heat 
necessary to power the intramolecular cyclization at a reasonable rate was not 
concentrated near the linker system, which may explain why the release percentages were 
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no better.  To determine whether suspension of the iron oxide is truly necessary for 
greater release, we added ~10 µL of commercial ferrofluid, EMG 304, FerroTec, into a 
solution of Fe@Au-LS1-FITC-PEG NPs 30.  The release profile was higher than that of 
Fe@Au NPs alone, with a maximum of 57% release after 60 minutes total exposure time.  
In addition, the temperature was significantly higher, with an average maximum bulk 
temperature solution of 47 °C after 15 minutes, a temperature well above any previous 
study we performed.  These promising results of increased percent payload release 
prompted us to improve the heating delivery as a means to increase the percent payload 
release.  This ultimately led to the use of water-soluble iron oxide NPs suspended in 
solution with LS1-FITC coated gold nanoparticles (GNP@LS1-FITC NPs). 
 
4.4. DUAL NANOPARTICLE OPTION 
 After finding more release and a higher bulk solution temperature with a greater 
concentration of iron oxide NPs in solution, we chose to explore how to optimize payload 
release with different concentrations of iron oxide added as part of a dual NP option.  We 
chose not to use Fe@Au NPs to circumvent any potential issues of variance between 
linker on the gold coating versus the amount of iron oxide present at the core due to size 
variance in iron oxide core diameter, but instead opted to use a dual NP system consisting 
of gold NPs (GNPs) and water-soluble magnetic iron oxide NPs (MNPs), as seen in 
Figure 4.23b.  This approach provided a platform for linker attachment (GNPs) with 
consistent variance in the amount of local hyperthermia generated (MNPs).  The 
mechanism of substrate release was already established from previous studies, which 
meant only LS1 needed testing.  Because Fe@Au-LS1-FITC 30 was water soluble, PEG-
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SH was not necessary, and concentration of GNPs in solution could be decreased since 
the theoretical amount of linker on 10 mgs of Fe@Au-LS1-FITC-PEG NPs 30 was about 
the same amount on 5 mg of GNP@LS1-FITC NPs.  In addition, we decreased the 
amount of LS1-FITC used for loading, and determined that only 0.01 mmol LS1-FITC 
per 1mg GNP was necessary.  GNP@LS1-FITC NPs were characterized via ζ-potential, 
DLS, and SEM.  ζ-potential showed a surface charge of -20.6 ± 1.63 mV.  DLS readings 
gave an average hydrodynamic diameter of 226.8 ± 26.77 nm, and SEM also shows 
aggregation of that size (Figure 4.18a).  Each individual particle, though, was much 
smaller, as seen in Figure 4.18b.  The fluorescence release was at a lower concentration, 
so the calibration curve maximum concentration value was decreased.  A new calibration 






Figure 4.18.  SEM of GNP@LS1-FITC.  a. Aggregation of NPs shows a 
diameter of 158.5 nm, consistent with DLS measurements.  b. Individual 







Figure 4.19.  FITC calibration curve for dual NP system (5 mg 
GNP@LS1-FITC with 5 mg, 10 mg, or 15 mg of MNP) to include 
concentration values 17 pM to 1.37 mM.  Concentrations were established 
through serial dilutions of FITC dissolved in 1X PBS buffer followed by 
fluorescence readings. 
 
The dual NP system was tested under the same conditions as in previous studies 
with AMF settings of 500 A (magnetic field strength of 1.98 kA/m) and 203 kHz, and 
exposure to an AMF for four 15-minute bursts.  Fluorescent readings were taken between 
each burst followed by 100% release through DTT incubation.  Each experiment 
contained a ratio of 5 mg of GNP@LS1-FITC NPs with either an equal, twice, or thrice 
amount of MNP by weight.  Each experiment was performed in triplicate, and the results 



























Figure 4.20.  Release profile at 500 A for GNP@LS1-FITC NPs:MNP at 
ratios of 1:1 (blue), 1:2 (red) and 1:3 (green), showing percent payload 
release after 4 15-minute bursts of exposure to an AMF (500A, 203 kHz).  
The 1:1 shows results similar to previous studies with Fe@Au.  
Significantly more release is seen with both 1:2 and 1:3, almost twice that 
of previous studies with Fe@Au.  The bar gives average release, and the 
error bars display standard deviation (n = 3). 
 
The data show that suspending iron oxide NPs in solution together with the GNP@LS1-
FITC NPs provides the necessary heat on AMF pulsing for payload release to occur.  A 
significant effect is noted when the amount of MNPs were twice or thrice that of GNPs. 
 We also explored the release profile of the same dual NP system ratios at a lower 
magnetic field strength (1.19 kA/m, or AMF setting of 300 A and 203 kHz).  With the 
lower magnetic field strength, we hypothesized that payload release would be less than 
that at 500 A because not as much local hyperthermia would be generated.  The dual NP 
system was tested under the same conditions as in previous studies with exposure to an 
AMF for 4 15-minute bursts with fluorescent readings taken between each burst followed 
























field strength of 1.19 kA/m) and 203 kHz.  Each experimental ratio was performed in 
triplicate, and the results are seen in Figure 4.21. 
 
 
Figure 4.21.  Release profile at 300 A for GNP@LS1-FITC NPs:MNP at 
ratios of 1:1 (blue), 1:2 (red) and 1:3 (green), showing percent payload 
release after 4 15-minute bursts of exposure to an AMF (300A, 203 kHz).  
Release is drastically reduced for each ratio in comparison to release at 
500 A, but percent release increases with a greater concentration of MNP.  
The bar gives average release, and the error bars display standard 
deviation (n = 3). 
 
As expected, the percent release at 300 A is lower than the percent release at 500 A.  This 
data also shows that the AMF exposure is responsible for the release of the payload, and 
its decrease substantially effected substrate release.  With a lower magnetic field strength, 
payload release to only 35% is seen.  In addition, as seen with the experiments at 500 A, 
an increased ratio of MNP to GNP@LS1-FITC NPs shows greater percent payload 
release.  Clearly, both the amount of MNP in solution, along with the AMF settings, 
























 Release profiles were also explored for each experimental ratio (i.e. GNP@ LS1-
FITC NPs with equal, twice, or thrice the amount of MNP) at physiological temperature 
(37 °C).  Each ratio was incubated in 1X PBS buffer for 2 1-hour intervals at 37 
°Cfollowed by centrifugation and analysis.  The release profiles after 1 hour for 1:1, 1:2, 
and 1:3 was 12%, 18%, and 24%, respectively.  After the second hour of incubation, the 
percent release for 1:1, 1:2, and 1:3 increased to 24%, 30%, and 41%, respectively.  
These values are much larger than the values from Fe@Au NPs.  The MNPs were coated 
in PEG following a literature procedure, but the release profiles suggest the PEG 
coverage is not complete.  One possibility is that the increased hydrolysis found by Knipp 
et al. is happening with the dual NP system at 37 °C, i.e. the iron oxide core is exposed 
and, because of its Lewis acidity, increased hydrolysis of the carbonate bond.  It is also 
possible that an exposed iron oxide core, which is anionic in nature, leads to local 
hyperbasicity upon exposure to an AMF for carbonate cleavage.  This result suggests 
controlling the amount added and quality of coating must be controlled. 
The Sun group first explored the synthesis of dumbbell-like Au-Fe3O4 NPs.5  
Briefly, the GNPs are synthesized, followed by epitaxial growth (i.e., “single crystalline 
material grows on single-crystalline substrate”)6 of Fe3O4 onto GNPs, which allows for 
two distinct surfaces onto which attachment can be made.  The Sun group later used the 
dumbbell-like NPs as a drug delivery system.7  A Her2-specific monoclonal antibody 
Herceptin was attached onto the iron oxide and a modified cisplatin was attached onto the 




Figure 4.22.  Dumbbell-like NPs with Herceptin attached to iron oxide NP via a catechol 
and cisplatin attached to gold via a thiol.  Adapted figure with permission from Nano 
Lett. 2005, 5, 379-382.  Copyright 2005 American Chemical Society. 
 
The functionalized NPs were incubated at 37 °C with Sk-Br3 cells (Her2-positive breast 
cancer cells) and MCF-7 cells (Her2-negative breast cancer cells).  As expected, the Her2 
receptor NPs better targeted the Sk-Br3 cells as compared to the MCF-7 cells.  In 
addition, 70% modified cisplatin was released into solution at pH 6 after one hour 
incubation at 37 °C.  By using a “dual NP” system that attaches the NPs together, 
distribution can be improved and both NPs arrive at the same intended destination.  If the 
dumbbell-like NPs were not attached, the 2nm and 8nm GNPs would largely be found in 




























Figure 4.23.  Different NP systems with exposure to AMF for payload release.  a. Core-
shell Fe@Au NPs with coating of PEG ( ) and linker in a ratio of 1:1.  Upon 
exposure to an AMF, the core creates local hyperthermia to induce intramolecular 
cyclization (amine = , carbonate = ) and payload release ().  b. Dual NP system with 
GNP coated with LS1-FITC and MNP.  Upon exposure to an AMF, the MNPs create 




 This thesis work has established that an alternating magnetic field can be used to 
cause substrate release from NP carriers (Figure 4.23).  We have shown for the first time 
that intramolecular cyclization of linkers attached to Fe@Au NPs can function as a 
triggerable mechanism for delivery.  The challenge of creating monodispersed, evenly 






using this NP system as a carrier.  The Fe@Au NPs we prepared and characterized were 
likely contaminated with substantial amounts of GNPs.  Despite that, our Fe@Au NP 
system clearly released payload (~40%) upon exposure to an AMF.  The dual NP system 
released payload at both a higher setting of 500 A – nearly complete release was seen – 
and a lower setting of 300 A.  The concentration of iron oxide greatly improved local 
hyperthermia generation and can improve release efficiency.  Because the premature 
payload release is a common problem when designing drug delivery systems containing 
Fe3O4, the carbonate moiety may not be ideal for further development.  The carbonate 
functionality proved not to withstand mild heating without payload release, as seen in the 
dual NP system.  If this remained the case with pure Fe@Au NPs, carbamate 
functionality would be the next option (Figure 4.24).  The delivery system described in 




Figure 4.24.  Modification of (a) LS1 from carbonate to (b) carbamate as 
indicated by the rectangle.  Upon exposure to AMF, the carbamate will 
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5.1. GENERAL STATEMENT 
Reagent grade solvents were used for extraction and flash chromatography.  
Acetonitrile was dried by distillation from CaH2.  All other commercial reagents were 
used as received without additional purification.  The progress of reactions was 
monitored by thin-layer chromatography (TLC) using pre-coated silica plates (EMD 
Silica Gel 60 F254).  Visualization was accomplished by staining plates with PMA (3% 
phosphomolybdic acid/ethanol solution) or PAA stain (2.5% p-anisaldehyde acid/ethanol 
solution).  UV active compounds were visualized by UV light (254 nm).  Silica gel 60 
(230-400 mesh) was used for flash column chromatography.  1H NMR spectra were 
recorded at 400 or 500 MHz, and 13C spectra were recorded at 100 or 125 MHz, 
respectively, in the indicated solvents.  The chemical shifts are reported in ppm values 
relative to the solvent residual peak CDCl3 (7.26 ppm for 1H NMR and 77.23 ppm for 13C 
NMR) or TMS (0.00 ppm for 1H NMR).  Coupling constants are reported in hertz (Hz).  
High-resolution mass spectra were obtained using a FT-ICR-MS system (LTQ FT, 
Thermo Electron Corp.) housed at the Center for Regulatory and Environmental 
Analytical Metabolomics (CREAM) Mass Spectrometry Facility, University of 
Louisville.  Fluorescent measurements were taken on a Perkin Elmer LS 55 fluorescence 
spectrometer at an excitation wavelength of 475 nm and emission wavelength of 525 nm. 
Fluorescent measurements were taken using a plastic VWR two-sided spectrophotometer 
cell with a 10 mm light path.  Scanning electron microscopy (SEM), transmission 
electron microscopy (TEM), and scanning transmission electron microscopy (STEM) was 
used to analyze size distribution and morphology of fabricated nanoparticles at the Conn 
Center for Renewable Energy Research, University of Louisville, Kentucky or at the 
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Nanotechnology Core Facility, University of Louisville, Kentucky.  For SEM and STEM, 
hexane-based (Fe@Au and GNPs) or water-based (Fe@Au-LS1-FITC NPs, GNP@LS1-
FITC NPs, and MNPs) nanoparticle dispersions were prepared and drop-casted on 
commercially available 200 mesh TEM support Cu grids coated with ultra thin carbon 
films.  After solvent evaporation, the samples were imaged on a 200 carbon/copper mesh 
with a Zeiss Supra Scanning Electron Microscope at a voltage between 10 kV and 25 kV.  
For TEM, water-based nanoparticle dispersions were prepared and drop-casted on 
commercially available 300 mesh TEM support Cu grids coated with ultra thin carbon 
films.  After water evaporation, samples were transferred to and analyzed using a field 
emission gun FEI Tecnaci F20 transmission electron microscope operating at the 
accelerating voltage of 200 kV.  Energy Dispersive A-ray Analysis (EDAX) was 
performed on the Zeiss SUPRA-FE-SEM (Peabody, MA) at 20 keV.  Samples were 
prepared on a carbon coated copper mesh grid with a working distance of 8 mm.  
Thermogravimetric analysis (TGA) measurements were made on a TA Instruments Hi-
Res TGA 2950 Thermogravimetric Analyzer using a Pt basket and maintaining a flow of 
N2 gas through the oven.  Each TGA experiment was run from 35 C to 800 C at a ramp 
rate of 20 °C/min.  UV/Vis readings were taken using a Varian Cary 50 Bio.  DLS and ζ-
potential measurements were taken using a Malvern Zetasizer: Nano-Zs90.  All 
measurements were taken using aqueous colloids of the nanoparticles in Millipore water.  
The alternating magnetic field (AMF) was generated with a Ambrell EasyHeat L1 set at 
either 499.6 amps or 300.2 A and 203 kHz using a 5-turn coil.  MALDI-TOF analysis 
was done on a Voyager DE-Pro MALDI-TOF instrument (PE Biosystems).  Sample 
preparation was provided by Bruker Guide to MALDI Sample Preparation.  Briefly, 
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sample solvent (30:70 v/v acetonitrile:0.1% TFA in water) was added to an equal amount 
of sample in liquid medium after testing.  The matrix solution was prepared by addition 
of 20 mg/mL 2,5-dihydroxybenzoic acid (2,5-DHB) to sample solvent.  This was added 
to an equal amount of sample in sample solvent and mixed vigorously.  0.5 µL sample + 
matrix was spotted onto a ground steel MALDI plate.  For matrix reference, 0.5 µL 
matrix solvent was spotted onto a ground steel MALDI plate as well.  Spectra were 
acquired in positive reflectron mode and calibration was achieved by using known peaks 




5.2. CHAPTER 2 EXPERIMENTAL PROCEDURES 
5.2.1.  Preparation of gold seeded iron oxide NPs 
Preparation of Fe3O4@APTES 
 Moditying the literature procedure of Montazerabadi et al.,1 3-
aminopropyl(triethoxysilane) (300 µL, 1.28 mmol) was added to iron oxide NPs (157.5 
mg, 0.68 mmol) and sonicated at rt for 30 minutes.  This mixture was heated at 60 C for 4 
h, followed by magnetic separation and washing with MeOH.  The NPs were dried in 
vacuo and characterized by FT-IR, which showed characteristic C-H stretch at 2929 cm-1 
and 2840 cm-1, N-H stretch  at 3358 cm-1, and Si-O-R stretch at 1043 cm-1 (Chapter 2, 
Figure 2.3). 
 
Preparation of Fe3O4@nAu 
 Modifying the literature procedure of Sharma et al.,2 CS2 (1.5 mL, 24.94 mmol) 
was added to a suspension of Fe3O4@APTES (157.5 mg) in borate buffer (1.5 mL) and 
stirred for 1 h at rt.  To this solution was added gold nanoseeds (1.5 mL of 10mM soln) 
and stirred rapidly overnight.  The NPs were magnetically separated and rinsed with DI 
water (5 x 1 mL) to give Fe3O4@nAu NPs.  Fe3O4@nAu NPs were characterized by HR-
TEM and EDAX (Chapter 2, Figure 2.4 and Figure 2.5), which showed inconsistent 
coating of gold nanoseeds onto the iron oxide core. 
 
Preparation of Fe@Au by reduction with ascorbic acid 
Modifying the literature procedure of Montazerabadi et al.,1 HAuCl4 (0.5 mL of 
10 mM soln) was added to Fe3O4@nAu NPs (18 mg) in water (2 mL) and sonicated for 
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30 mins at rt.  To the suspension was added ascorbic acid (100 mg, 0.57 mmol) and 
stirred vigorously for 2 h, followed by magnetic separation and washing with water until 
supernatant was clear (2 x 5 mL) then resuspended in water (10 mL)  to give Fe@Au 
NPs.  These NPs were characterized via UV-Vis, DLS, and ζ-potential.  UV-Vis did not 
show a SPR band, DLS revealed an average hydrodynamic diameter of 2500 nm, and ζ-
potential showed an average surface charge of -6.0 mV.   
 
Preparation of Fe@Au by reduction with sodium citrate 
Modifying the literature procedure of Hu et al.,3  HAuCl4 (0.5 mL of 10 mM 
soln) was added to Fe3O4@nAu NPs (18 mg,) in water (200 mL) while stirring 
vigorously then immediately heated to 100 °C and held there for 10 minutes.  To this 
solution was added sodium citrate (10 mL of 5 wt % soln) and stirred for another 20 
minutes at 100 °C.  Upon cooling, the NPs were magnetically separated and washed with 
DI water (2 x 10 mL) then resuspended in water (10 mL)  to give Fe@Au NPs.  These 
NPs were characterized via UV-Vis, DLS, and ζ-potential.  UV-Vis did not show a SPR 
band, DLS revealed an average hydrodynamic diameter of 3000 nm, and ζ-potential 
showed an average surface charge of -42.0 mV.   
 
Preparation of Fe@Au by reduction with glucose 
Modifying the literature procedure of Mandal et al.,4 glucose (0.5 g, 2.77 mmol), 
Fe3O4@nAu NPs (18 mg), and HAuCl4 (0.5 mL of 10 mM soln) were added together 
and sonicated for 15 mins., then heated at 35-40 °C for 1 h.  The NPs were magnetically 
separated and washed with DI water (3 x 5 mL) then resuspended in water (10 mL) to 
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give Fe@Au NPs.  These NPs were characterized via UV-Vis, DLS, and ζ-potential.  
UV-Vis did not show a SPR band, DLS revealed a cluster of NPs with hydrodynamic 
diameter of 700 and 200 nm, and ζ-potential showed an average surface charge of +32.2 
mV.   
 
Preparation of Fe@Au by reduction with sodium borohydride 
Modifying the literature procedure of Rivas,5  sodium borohydride (10 mL of 
0.6M soln) was added to Fe3O4@nAu NPs (18 mg), followed by addition of HAuCl4 (1 
mL of 10mM soln) and stirred vigorously at rt for 5 h.  The NPs were magnetically 
separated and washed with DI water (5 mL) then resuspended in water (10 mL) to give 
Fe@Au NPs.  These NPs were characterized via UV-Vis, DLS, and ζ-potential.  UV-Vis 
did not show a SPR band, DLS revealed an average hydrodynamic diameter of 2400 nm, 
and ζ-potential showed an average surface charge of -15.7 mV.   
 
5.2.2. Fe@Au NPs 
 Modifying the literature procedure of Park et al.,6 FeCl3·6H2O (540.6 mg, 2 
mmol), FeCl2·6H2O (198.8 mg, 1 mmol), and C18H33ONa (2.4 g, 8 mmol) were dissolved 
in ethanol (6 mL), deoxygenated water (4.5 mL), and toluene (10.5 mL).  This mixture 
was heated at 74 °C for 4 h under nitrogen.  The resulting black mixture was cooled to 
room temperature and ethanol (50 mL) was added to precipitate the particles.  The 
mixture was centrifuged at 4000 rpm for 10 min at 4 °C to pellet.  A clear, light orange 
supernatant was decanted off and the residual black pellet was re-dispersed in hexane (5 
mL) by vortexing.  Redispersed particles were precipitated with ethanol (40 mL) then 
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centrifuged at 4000 rpm for 10 min at 4 °C to pellet.  Redispersal, precipitation, and 
centrifugation were repeated two more times.  The pelleted particles were redispersed in 
hexane (40 mL) and undispersed residues removed by centrifugation at 4000 rpm for 5 
min at 4 °C.  The resulting black supernatant was decanted, and hexane removed in vacuo 
to obtain nanoparticles in solid form.  Nanoparticles were stored under nitrogen at rt until 
further use.  NPs were analyzed via HR-TEM, EDAX, and SQUID (Chapter 2, Figure 
2.6).  HR-TEM revealed an average diameter of 5 ± 1 nm with good monodispersity.  
EDAX gave characteristic peaks for iron oxide.  The Cu peaks are due to the copper grid 
used for analysis.  SQUID measurements showed a magnetic saturation of 0.3 emu/g with 
no hysteresis loop at room temperature.  This indicated superparamagnetic NPs because a 
hysteresis loop should not be detected above the blocking temperature, in this case 27 °C. 
Modifying the literature procedure of Wang et al.,7 a solution of as prepared iron 
oxide NPs (16 mg, 0.07 mmol), gold (III) acetate (80 mg, 0.2 mmol), oleic acid (50 µL, 
0.15 mmol), oleylamine (300 µL, 0.911 mmol), and 1,2-tetradecandiol (0.3 g, 1.3 mmol) 
in phenyl ether (10 mL) under nitrogen was heated at 185 °C for 1.5 h.  After cooling to 
rt, EtOH (40 mL) was added to precipitate the core/shell NP.  The mixture was 
centrifuged at 3000 rpm for 5 min and the supernatant was discarded.   The precipitate 
was redissolved in hexane (5 mL), followed by addition of EtOH 40 mL).  The mixture 
was centrifuged at 3000 rpm for 10 min and the upper purple GNP solution was 
discarded. This process was repeated 5 times. The core/shell NP was collected after 
centrifuge and NP were stored in solid form under nitrogen at rt until further use.  NPs 
were characterized via STEM, EDAX, UV-Vis, and SQUID (Chapter 2, Figure 2.7, 
Figure 2.8, Figure 2.9).  STEM revealed an average NP diameter of 7 ± 3 nm with 
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relatively good monodispersity, consistent with literature values.2  EDAX showed 
characteristic peaks for both iron oxide and gold based on literature. 2  UV-Vis analysis 
showed a characteristic surface plasmon resonance around 530 nm, consistent with 
literature values. 2  SQUID measurements showed a magnetic saturation of 6 emu/g with 
no detectable hysteresis loop above the blocking temperature of 27 °C.   
 
5.2.3. Gold NPs 
Modifying the literature procedure of de la Presa et al,8 to a rb flask a solution of 
gold (III) acetate (100 mg, 0.27 mmol) and 1,2-tetradecanediol (500 mg, 2.17 mmol) in 
phenylether (30 mL) were added at rt.  The solution was heated up to 80 °C under 
nitrogen, then oleic acid (0.32 mL, 1.01 mmol) and oleylamine (0.34 mL, 1.03 mmol) 
were added and heated to reflux (260 °C) for 30 minutes.  After cooling to room 
temperature, the GNPs were precipitated by adding EtOH (40 mL) and pelleted via 
centrifugation at 3000 rpm for 5 min and the supernatant was discarded.   The precipitate 
was redissolved in hexane (5 mL), followed by addition of EtOH (40 mL).  The mixture 
was centrifuged at 3000 rpm for 10 min and the supernatant was discarded.  This was 
done once more, and after the final removal of supernatant, the NPs were dried in vacuo 
and stored in solid form under nitrogen at room temperature until further use.  NPs were 
characterized via DLS and SEM (Chapter 2, Figure 2.10).  DLS revealed a hydrodynamic 





5.2.4. Water-soluble iron oxide NPs 
Modifying the literature procedure of García-Jimeno and Estelrich,9 PEG 2K (6.0 
g, 3 mmol) was dissolved in a rb flask containing water (5 mL) while stirring at 45 °C.  
To this was added FeCl24H2O (0.16 g, 0.8 mmol) and FeCl36H2O (0.435 g, 1.6 mmol). 
After dissolution, NH4OH (10 mL of a 0.75M solution) was added under vigorous 
stirring and stirred a further 30 min.  Upon cooling to rt, the MNPs were poured into a 
beaker and placed on a neodymium magnet (N52 neodymium 1” magnetic cube, Applied 
Magnets, Texas).  The supernatant was decanted and the MNPs were washed four more 
times with water.  Water was added until the desired concentration was achieved and 
sonicated for 12 minutes.  NPs were characterized by ζ–potential, DLS and SEM ( 
Chapter 2, Figure 2.11).  ζ–potential showed a surface charge of -22.4 ± 2.02 mV.  DLS 
showed a hydrodynamic diameter of 716.2 ± 74.3 nm, whereas SEM gave a diameter of 





5.3. CHAPTER 3 EXPERIMENTAL PROCEDURES 
5.3.1. Amine Linker 
 
4-((tert-Butyldimethylsilyl)oxy)butan-1-ol.  A solution of TBSCl (6.00 g, 39.8 mmol) in 
dry CH2Cl2 (100 mL) was added dropwise over 1 h to a solution of 1,4-butanediol (16.9 
mL, 191 mmol) and Et3N (7.77 mL, 55.7 mmol) in dry CH2Cl2 (100 mL) at 0 °C.  The 
reaction mixture was stirred overnight at rt. The solvent was removed in vacuo and the 
remaining oil was extracted with hexanes (4x) and the combined extractions were washed 
twice with sat. NH4Cl, once with brine, and then dried over Na2SO4, filtered and 
concentrated in vacuo to afford crude 4-((tert-butyldimethylsilyl)oxy)butan-1-ol (7.28 g, 
89%) as a colorless oil.  This material was used in the next step without further 
purification.  Spectral characteristics agreed with published data.10  IR ν (cm-1) 3349; 1H 
NMR (400 MHz, CDCl3) δ 0.07 (s, 6H), 0.90 (s, 9H), 1.60-1.69 (m, 2H), 2.86 (br s, 1H), 
3.62-3.68 (m, 4H); 13C NMR (100 MHz, CDCl3) δ -5.4, 18.3, 25.9, 29.8, 30.1, 62.7, 63.4.  
HRMS m/z cald [C10H25O2Si]+ 205.1618, observed 205.1618. 
 
 
4-((tert-Butyldimethylsilyl)oxy)butyl methanesulfonate.  Methanesulfonyl chloride 
(1.09 mL, 14.1 mmol) was added to a solution of crude 4-((tert- 
butyldimethylsilyl)oxy)butan-1-ol (2.51 g, 12.3 mmol) and Et3N (2.59 mL, 18.4 mmol) in 
dry CH2Cl2 (50 mL) at 0 °C and the reaction mixture was stirred for 2 h at 0 °C and 




CH2Cl2. The combined organic phases were washed once with brine and then dried over 
Na2SO4, filtered and concentrated in vacuo to afford 4-((tert-butyldimethylsilyl)oxy)butyl 
methanesulfonate (3.22 g, 93%) as an orange oil.  This material was used without further 
purification.  IR ν (cm-1) 1173, 1426;  1H NMR (400 MHz, CDCl3) δ 0.05 (s, 6H), 0.89 
(s, 9H), 1.63 (m, 2H), 1.84 (m, 2H), 3.00 (s, 3H), 3.65 (t, J = 6.0 Hz, 2H), 4.27 (t, J = 6.8 




Phthalimide (3.19 g, 21.7 mmol) was added to a solution of 4-((tert- 
butyldimethylsilyl)oxy)butyl methanesulfonate (3.22 g, 11.4 mmol) and K2CO3 (1.89 g, 
13.7 mmol) in DMSO (40 mL).  The solution was heated to 75 °C for 17 h. The reaction 
was then cooled to rt and quenched with water. The aqueous solution was extracted with 
EtOAc (4x) and the combined organic phases were washed with water (3x). The organic 
phase was then washed with brine, dried over Na2SO4, filtered and concentrated in vacuo 
to afford 2-(4-((tert-butyldimethylsilyl)oxy)butyl)-2,3-dihydro-1H- isoindole-1,3-dione 
as white crystals, mp 188-190 °C, and was used without further purification.  IR ν (cm-1) 
1707;  1H NMR (400 MHz, CDCl3) δ 0.04 (s, 6H), 0.88 (s, 9H), 1.53-1.60 (m, 2H), 1.71-
1.79 (m, 2H), 3.64 (t, J = 6.2 Hz, 2H), 3.72 (t, J = 7.2 Hz, 2H), 7.71 (dd, J = 3.0, 5.4 Hz, 
2H), 7.84 (dd, J = 3.2, 5.2 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ -5.2, 18.5, 25.3, 26.2, 






(4-Aminobutoxy)(tert-butyl)dimethylsilane (11).  Hydrazine monohydrate (2.95 mL, 
60.9 mmol) was added to a solution of crude 2-(4-((tert-butyldimethylsilyl)oxy)butyl)-
2,3- dihydro-1H-isoindole-1,3-dione (4.06 g, 12.2 mmol) in 2:1 CH2Cl2:EtOH (60 mL) at 
0 °C.  The reaction mixture was stirred overnight, allowing the reaction to come to rt. The 
solution was diluted with CH2Cl2, the white precipitate was filtered, and the filter cake 
was washed with ample CH2Cl2. The crude solution was concentrated in vacuo to afford 
11 (2.37 g, 98% over 2 steps) as a light yellow oil, having spectral characteristics in 
agreement with published data,11 and was used without further purification.  IR ν (cm-1) 
3024, 3058; 1H NMR (400 MHz, CDCl3) δ 0.06 (s, 6H), 0.89 (s, 9H), 1.60-1.67 (m, 2H), 
1.79-1.87 (m, 2H), 3.01 (t, J = 7.2 Hz, 2H), 3.65 (t, J = 6.0 Hz); 13C NMR (100 MHz, 
CDCl3) δ -5.3, 18.2, 24.6, 25.9, 29.7, 39.9, 62.3.  HRMS m/z cald [C10H26NOSi]
+ 
204.1778, observed 204.1779. 
 
 
 (((3-Bromopropyl)sulfanyl)diphenylmethyl)benzene (12).  K2CO3 (0.80 g, 5.8 mmol) 
followed by 1,3-dibromopropane (2.67 mL, 26.6 mmol) was added to a solution of 
triphenylmethanethiol (1.5 g, 5.4 mmol) in dry THF (27 mL) under N2. The reaction was 
refluxed for 24 h before cooling to rt. The reaction solution was washed twice with water, 
extracted twice with Et2O, washed with brine, dried over Na2SO4, filtered and 






afford 12 (1.99 g, 92%) as white crystals, mp 85-86 °C, (lit 90-92 °C) having spectral 
characteristics in agreement with published data.12  IR ν (cm-1) 660, 1254; 1H NMR (400 
MHz, CDCl3) δ 1.78-1.85 (m, 2H), 2.33 (t, J = 7.0 Hz, 2H), 3.33 (t, J = 6.6 Hz, 2H), 
7.20-7.31 (m, 9H), 7.41-7.43 (m, 6H); 13C NMR (100 MHz, CDCl3) δ 30.5, 31.8, 32.5, 
66.9, 126.9, 128.1, 129.8, 144.9.   
 
 
12,12,13,13-Tetramethyl-1,1,1-triphenyl-11-oxa-2-thia-6-aza-12-silatetradecane (13).  
(((3-Bromopropyl)sulfanyl)diphenylmethyl)benzene (742 mg, 1.87 mmol) was added to a 
solution of (4-aminobutoxy)(tert-butyl)dimethylsilane (950 g, 4.68 mmol) in MeCN (20 
mL) and the reaction was heated to 55 °C for 24 h. After cooling to rt, the reaction was 
quenched with sat. NaHCO3 and extracted three times with EtOAc. The combined 
organic phases were washed with brine, dried over Na2SO4, filtered and concentrated in 
vacuo. The crude material was purified by column chromatography (SiO2, 0:1 to 1:4, 
MeOH:CH2Cl2with 1% NH4OH gradient) to give 13 (692 mg, 71%) as an orange oil.  IR 
ν (cm-1) 697, 3300; 1H NMR (400 MHz, CDCl3) δ 0.04 (s, 6H), 0.89 (s, 9H), 1.45-1.52 
(m, 4H), 1.53-1.60 (m, 2H), 2.19 (t, J = 7.2 Hz, 2H), 2.52 (q, J = 7.2 Hz, 4H), 3.60 (t, J = 
5.8 Hz, 2H), 7.17-7.28 (m, 9H), 7.40-7.42 (m, 6H); 13C NMR (100 MHz, CDCl3) δ -5.1, 
18.5, 26.1, 26.7, 29.1, 29.9, 30.8, 49.0, 49.8, 63.2, 66.7, 126.7, 128.0, 129.7, 145.1.  









propyl)carbamate.  Boc2O (327 mg, 11.5 mmol) was added to a solution of 12,12,13,13-
tetramethyl-1,1,1-triphenyl-11-oxa-2-thia-6-aza-12-silatetradecane (710 mg, 1.37 mmol) 
and Et3N (211 µL, 1.5 mmol) in CH2Cl2 (14 mL) at 0 °C. After 3 h, the reaction solution 
was washed twice with sat. NH4Cl and the aqueous phase was extracted twice with 
CH2Cl2. The combined organic phases were washed with brine, dried over Na2SO4, 
filtered and concentrated in vacuo to afford crude tert-butyl N-(4((tert- 
butyldimethylsiyl)oxy)butyl)-N-(3-((triphenylmethyl)sufanyl)propyl)carbamate as an 
orange oil and was used without further purification.  IR ν (cm-1) 1693; 1H NMR (400 
MHz, CDCl3) δ 0.04 (s, 6H), 0.88 (s, 9H), 1.39 (br s, 4H), 1.45 (br s, 2H), 1.53 (s, 9H), 
2.13 (t, J = 7.6 Hz, 2H), 3.05 (br s, 4H), 3.58 (t, J = 5.6 Hz, 2H), 7.18-7.29 (m, 9H), 7.39-
7.41 (m, 6H); 13C NMR (100 MHz, CDCl3) δ -5.1, 18.5, 25.4, 26.2, 27.6, 28.6, 29.6, 30.3, 
46.5, 47.0, 63.0, 66.8, 79.3, 126.8, 128.1, 129.8, 145.1, 155.6.   
 
 
tert-Butyl N-(4-hydroxybutyl)-N-(3-((triphenylmethyl)sulfanyl)propyl)carbamate.  
TBAF (1.5 mL of 1 M solution in THF, 1.5 mmol) was added to a solution of crude tert-
butyl N-(4((tert-butyldimethylsiyl)oxy)butyl)-N-(3-((triphenylmethyl)sufanyl) 
propyl)carbamate (1.4 mmol) in dry THF (5 mL) at 0 °C.  The reaction mixture was 






TLC analysis, the reaction was washed twice with sat. NaHCO3 and the combined 
aqueous phases were extracted three times with Et2O. The combined organic layers were 
washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The crude 
material was purified by column chromatography (SiO2, 3:7, EtOAc:CH2Cl2) to give 
tert-butyl N-(4-hydroxybutyl)-N-(3-((triphenylmethyl)sulfanyl)propyl)carbamate (673 
mg, 98% over 2 steps) as a light yellow oil.  IR ν (cm-1) 1669, 3426; 1H NMR (400 MHz, 
CDCl3) δ 1.39 (s, 9H), 1.45-1.51 (m, 4H), 1.54-1.58 (m, 2H), 2.14 (t, J = 7.2 Hz, 2H), 
2.29 (br s, 1H), 3.05 (br s, 4H), 3.60 (t, J = 5.6 Hz, 2H), 7.17-7.28 (m, 9H), 7.39-7.41 (m, 
6H); 13C NMR (100 MHz, CDCl3) δ 24.9, 28.0, 28.6, 29.6, 29.8, 46.6, 46.9, 62.4, 66.8, 




4-(((tert-Butoxy)carbonyl)((3-((triphenylmethyl)sulfanyl)propyl))amino) butyl 1H- 
imidazole-1-carboxylate (14).  1,1’-Carbonyldiimidazole (154 mg, 0.95 mmol) was 
added to a solution of tert-butyl N-(4-hydroxybutyl)-N-(3-
((triphenylmethyl)sulfanyl)propyl) carbamate (320 mg, 0.63 mmol) and (i-Pr)2NEt (166 
µL, 0.95 mmol) in dry CH2Cl2 (2 mL) at 0 °C.  The mixture was stirred overnight, 
allowing the reaction to warm to rt. The reaction solution was washed twice with water 
and extracted once with CH2Cl2. The combined organic layers were washed twice with 






to afford crude 5 (350 mg, 92%) as a light yellow oil and was used without further 
purification.  IR ν (cm-1) 1686, 1760; 1H NMR (400 MHz, CDCl3) δ 1.39 (s, 9H), 1.52-
1.61 (m, 4H), 1.70-1.77 (m, 2H), 2.15 (t, J = 7.2 Hz, 2H), 3.09 (br s, 4H), 4.40 (t, J = 6.6 
Hz, 2H), 7.06 (s, 1H), 7.18-7.29 (m, 9H), 7.39-7.41 (m, 7H), 8.13 (s, 1H); 13C NMR (125 
MHz, CDCl3) δ 24.6, 26.0, 28.2, 28.5, 29.5, 46.5 (2 C’s), 66.8, 68.1, 79.6, 117.2, 126.7, 
128.0, 129.7, 130.8, 137.2, 144.9, 148.8, 155.4.  HRMS m/z cald [C35H42N3O4S]+ 




butoxy)carbonyl)oxy)ethoxy)-2,3-dihydro-1H-isoindole-1,3-dione.  DBU (434 µL, 
2.80 mmol) was added to a solution of crude tert-butyl N-(4-hydroxybutyl)-N-(3- 
((triphenylmethyl)sulfanyl)propyl)carbamate (1.64 g, 2.80 mmol) in dry MeCN (12 mL). 
After stirring for 10 min, 2-(2-hydroxyethoxy)-2,3-dihydro-1H-isoindole-1,3-dione (579 
mg, 2.80 mmol) was added and the reaction was stirred overnight. Upon completion, the 
reaction was washed twice with sat. NH4Cl and the combined aqueous layers were 
extracted three times with EtOAc. The combined organic layers were washed with brine, 
dried over Na2SO4, filtered and concentrated in vacuo. The crude material was purified 
by column chromatography (SiO2, 3:17, EtOAc:CH2Cl2) to give 2-(2-(((4-(((tert- 
butoxy)carbonyl)((3-((triphenylmethyl)sulfanyl) propyl))amino)butoxy)carbonyl)oxy) 







1) 1685, 1733, 1793; 1H NMR (400 MHz, CDCl3) δ 1.40 (s, 9H), 1.48-1.60 (m, 6H), 2.16 
(t, J = 7.0 Hz, 2H), 3.06 (br s, 4H), 4.14 (t, J = 5.2 Hz, 2H), 4.43-4.44 (m, 4H), 7.18-7.28 
(m, 9H), 7.39-7.41 (m, 6H), 7.69-7.72 (m, 2H), 7.91-7.81 (m, 2H); 13C NMR (100 MHz, 
CDCl3) δ 24.6, 26.1, 28.2, 28.6, 29.5, 46.5, 46.6, 65.2, 66.8, 68.1, 75.7, 79.5, 123.8, 
126.8, 128.0, 129.0, 129.7, 134.8, 145.0, 155.1, 155.5, 163.5.  HRMS m/z cald 




((triphenylmethyl)sulfanyl)propan-1-amine (15).  Hydrazine monohydrate (356 µL, 
7.3 mmol) was added to a solution of 2-(2-(((4-(((tert-butoxy)carbonyl)((3- 
((triphenylmethyl)sulfanyl)propyl))amino)butoxy)carbonyl) oxy)ethoxy)-2,3-dihydro- 
1H-isoindole-1,3-dione (1.08 g, 1.5 mmol) in CH2Cl2at 0 °C and stirred for 2 h. When 
complete, the white precipitate was removed by filtration and the filter cake was washed 
with ample CH2Cl2. The filtrate was concentrated in vacuo to afford 6 (899 mg, 99%) as 
a colorless oil and was used without further purification.  IR ν (cm-1) 1687, 1744, 3323; 
1H NMR (400 MHz, CDCl3) δ 1.39 (s, 9H), 1.50-1.62 (m, 6H), 2.14 (t, J = 7.2 Hz, 2H), 
3.05 (br s, 4H), 3.85 (t, J = 4.2 Hz, 2H), 4.13 (t, J = 6.2 Hz, 2H), 4.32 (t, J = 4.4 Hz, 2H), 
5.52 (br s, 2H), 7.18-7.29 (m, 9H), 7.39-7.41 (m, 6H); 13C NMR (100 MHz, CDCl3) 
δ 24.7, 26.2, 27.5, 28.6, 29.5, 46.7 (2 C’s), 65.5, 66.8, 68.0, 73.4, 79.5, 126.8, 128.0, 






5.3.2. Amine-free Linker 
 
6-(Tritylthio)hexan-1-ol.  6-bromohexanol (0.526 g, 2.90 mmol), triphenylmethanethiol 
(0.802 g, 2.90 mmol), and K2CO3 (0.802 g, 5.80 mmol) were added to a 1:1 mixture of 
ethanol:water (15.0 mL) and the reaction was heated to 90 °C for 18 h.  After cooling to 
rt, the reaction was quenched with 1M HCl and extracted three times with CH2Cl2. The 
combined organic layers were washed with water, brine, dried over anhydrous Na2SO4, 
filtered, and concentrated in vacuo to give 6-(tritylthio)hexan-1-ol (0.88 g, 82%) as a 
yellow oil and was used without further purification.  IR ν (cm-1) 3362; 1H NMR (500 
MHz, CDCl3) δ 1.19-1.30 (m, 4H), 1.37-1.43 (m, 2H), 1.45-1.50 (m, 2H), 2.14 (t, J = 7.5 
Hz, 2H), 3.58 (t, J = 6.5 Hz, 2H), 7.19-7.29 (m, 9H), 7.40-7.42 (m, 6H); 13C NMR (100 
MHz, CDCl3) δ 25.5, 28.8, 32.1, 32.7, 63.0, 66.6, 126.7, 128.0, 129.8, 145.2. 
 
 
6-(Tritylthio)hexyl 1H-imidazole-1-carboxylate (17).  1,1’-carbonyldiimidazole (1.27 
g, 7.86 mmol) was added to a solution of N,N-diisopropylethylamine (1.02 g, 7.86 mmol) 
and 6-(tritylthio)hexan-1-ol (1.97 g, 5.24 mmol) in CH2Cl2 (25 mL) at 0 °C and was 
stirred overnight. The reaction mixture was washed twice with water and extracted once 
with CH2Cl2. The combined organic layers were washed twice with sat. NH4Cl, once 
with brine, were dried over anhydrous Na2SO4, and concentrated in vacuo to give 8 as a 
yellow oil and was used without further purification.  IR ν (cm-1) 1768; 1H NMR (500 







7.0 Hz, 2H), 4.35 (t, J = 6.5 Hz, 2H), 7.11 (s, 1H), 7.19-7.29 (m, 9H), 7.40-7.42 (m, 6H), 
8.11 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 25.4, 28.4, 28.6, 31.7, 66.6, 68.4, 117.2, 
126.7, 128.1, 129.7, 130.8, 137.2, 145.1, 148.9; HRMS m/z cald [C29H32N2O2S]+ 
471.2101, observed 471.2096. 
 
 
2-((6-(Tritylthio)hexyl)oxy)isoindoline-1,3-dione.  DBU (1.65 mL, 11.1 mmol) was 
added to a solution of crude 6-(tritylthio)hexyl 1H-imidazole-1-carboxylate (5.21 g, 11.1 
mmol)  in dry MeCN (50 mL).  After stirring for 10 min, N-(2-Hydroxyethyl)phthalimide 
(2.29 g, 11.1 mmol) was added and the reaction was stirred overnight.  Upon completion, 
the reaction was washed twice with sat. NH4Cl and the combined aqueous layers were 
extracted three times with EtOAc.  The combined organic layers were washed with brine, 
dried over Na2SO4, filtered and concentrated in vacuo.  The crude material was purified 
by column chromatography (SiO2, 3:7 Hex:EtOAc) to give 2-((6-
(tritylthio)hexyl)oxy)isoindoline-1,3-dione (4.48 g, 66% over 2 steps) as a clear oil.  IR ν 
(cm-1) 1735, 1793; 1H NMR (500 MHz, CDCl3) δ 1.19-1.27 (m, 4H), 1.36-1.41 (m, 2H), 
1.54-1.59 (m, 2H), 2.13 (t, J = 7.5 Hz, 2H), 4.08 (t, J = 7.0 Hz, 2H), 4.43-4.47 (m, 4H), 
7.19-7.29 (m, 9H), 7.40-7.42 (m, 6H), 7.73-7.75 (m, 2H), 7.83-7.84 (m, 2H); 13C NMR 
(100 MHz, CDCl3) δ 25.4, 28.4, 28.6, 32.0, 65.2, 66.6, 68.4, 75.7, 123.8, 126.7, 128.0, 









O-(6-(Tritylthio)hexyl)hydroxylamine (18).  Hydrazine monohydrate (2.16 g, 43.11 
mmol) was added to a solution of 2-((6-(tritylthio)hexyl)oxy)isoindoline-1,3-dione (5.25 
g, 8.62 mmol) in CH2Cl2 (100 mL) at 0 °C and stirred for 2 h. When complete, the white 
precipitate was removed by filtration and the filter cake was washed with ample CH2Cl2.  
The filtrate was concentrated in vacuo to afford 9 (4.06 g, 98%) as a colorless oil and was 
used without further purification.  IR ν (cm-1) 1749, 3334; 1H NMR (500 MHz, CDCl3) δ 
1.21-1.29 (m, 4H), 1.36-1.41 (m, 2H), 1.54-1.61 (m, 2H), 2.14 (t, J = 7.0 Hz, 2H), 3.86 
(t, J = 4.0 Hz, 2H), 4.07 (t, J = 6.5 Hz, 2H), 4.33 (t, J = 4.5 Hz, 2H), 5.52 (s, 1H), 7.19-
7.29 (m, 9H), 7.40-7.41 (m, 6H); 13C NMR (100 MHz, CDCl3) δ 25.4, 28.5, 28.7, 31.9, 
65.4, 66.6, 68.2, 73.4, 126.7, 127.9, 129.8, 145.2, 155.6; HRMS m/z cald [C28H34NO4S]+ 








5.4. CHAPTER 4 EXPERIMENTAL PROCEDURES 
5.4.1. Preparation of Fe@Au@LS-anthracene NPs 
TGA calculation for LS loading 
The amount of linker per milligram of NP was calculated based off TGA data 
seen in Chapter 4.  Briefly:  
 
a. Total amount of LS1-anthracene lost is equivalent to total amount loaded onto NPs.  
This amount is converted to mmol using molecular weight (465.2 g/mol). 
b. Total amount of Fe@Au NPs is calculated by subtracting the amount of LS1-
anthracene lost from the total weight. 
c. Conversion: if 4.3 x 10-4 mmol LS1-anthracene loaded for 2.2555 mg Fe@Au NPs, 
then 1.9 x 10-4 would be loaded onto 1 mg Fe@Au NPs. 
 
Calculations determined the amount of LS1-anthracene loaded onto 1 mg of NP to be 
0.0002 mmol.  In our preparation, we used 100 times excess linker, or 0.02 mmol, per 
milligram NP.   
 
Preparation of protected LS1-anthracene 19 
Anthracene-CHO (296.4 mg, 1.35 mmol) was added to 15 (820.6 mg, 1.35 mmol) 
in CH2Cl2 (5 mL) at room temperature and stirred overnight.  Upon completion as 
determined by TLC analysis, the reaction concentrated in vacuo to afford 19 (1.08 g, 
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99%) as an orange oil and was used without further purification.  IR ν (cm-1) 1684, 1724, 
1741; 1H NMR (500 MHz, CDCl3) major isomer δ 1.38 (s, 9H), 1.45-1.65 (m, 6H), 2.13 
(t, J = 7.5 Hz, 2H), 3.04 (br s, 4H), 3.72 (t, J = 4.5 Hz, 2H), 4.13 (t, J = 6.5 Hz, 2H), 4.33 
(t, J = 5.0 Hz, 2H), 4.50 (d, J = 6.5 Hz, 2H), 7.18-7.27 (m, 9H), 7.39-7.40 (m, 6H), 7.46-
7.52 (m, 4H), 8.02 (d, J = 8.5 Hz, 2H), 8.17 (d, J = 8.5 Hz, 2H), 8.42 (s, 1H); 13C NMR 
(100 MHz, CDCl3) major isomer δ 24.7, 25.4, 26.2, 28.6, 29.5, 43.3, 46.7 (2 C’s), 66.2, 
66.5, 67.8, 71.3, 79.5, 124.0, 125.3, 126.4, 126.8, 127.4, 128.0, 129.5, 129.8, 130.3, 
131.7, 134.3, 145.0, 149.6, 155.5.   
 
Preparation of protected LS2-anthracene 23 
Anthracene-CHO (495.4 mg, 2.25 mmol) was added to 18 (1.08 g, 2.25 mmol) in 
CH2Cl2 (10 mL) at room temperature and stirred overnight.  Upon completion as 
determined by TLC analysis, the reaction concentrated in vacuo to afford 23 (1.53 g, 
99%) as an orange oil and was used without further purification.  IR ν (cm-1) 1669, 1744; 
1H NMR (400 MHz, CDCl3) major isomer δ 1.17-1.28 (m, 4H), 1.32-1.40 (m, 2H), 1.50-
1.66 (m, 2H), 2.11 (t, J = 9.0 Hz, 2H), 4.03 (t, J = 8.5 Hz, 2H), 4.32 (t, J = 6.5 Hz, 2H), 
4.51 (d, J = 7.0 Hz, 2H), 7.19-7.29 (m, 9H), 7.39-7.41 (m, 6H), 7.46-7.50 (m, 4H), 8.02 
(d, J = 10.0 Hz, 2H), 8.30 (d, J = 10.5 Hz, 2H), 8.42 (s, 1H); 13C NMR (100 MHz, 
CDCl3): δ 25.2, 25.3, 28.5, 31.9, 66.0, 66.5, 68.0, 71.2, 124.0, 125.1, 126.2, 126.6, 127.2, 





Preparation of LS-anthracene (20 and 24) 
To prepare LS1-anthracene for loading onto Fe@Au NPs, protected LS1-
anthracene (364.8 mg, 0.45 mmol) was dissolved in CH2Cl2 (5 mL) at 0 °C.  TFA (5 mL, 
65 mmol) was added dropwise, followed by Et3SiH (215.5 µL, 1.35 mmol) added 
dropwise.  The mixture was stirred at 0 °C for 30 mins.  Upon completion as determined 
by TLC analysis, the reaction was warmed to rt, concentrated in vacuo, and used crude 
immediately for addition to NPs.  Both 20 and 24 followed this procedure. 
 
Preparation of Fe@Au-LS-anthracene NPs (21 and 25) 
LS1-anthracene 20 (112.32 mg, 0.24 mmol) was redissolved in CH2Cl2 (6.4 mL), 
then added to a solution of rapidly stirring Fe@Au NPs (6 mg) in hexane (15 mL) over 4 
hours, followed by precipitation with EtOH (40 mL).  NPs were pelleted via 
centrifugation at 10K rpm for 15 minutes.  The supernatant was discarded, the NPs were 
redissolved in CH2Cl2 (5 mL) and precipitated with EtOH (45 mL).  NPs were pelleted 
via centrifugation at 10K rpm for 15 minutes, and the supernatant was discarded.  This 
washing process was performed 4 more times.  After the final discard of supernatant, the 
NPs were dried in vacuo and stored in solid form under nitrogen at rt until further use.   
Both 21 and 25 were prepared in this manner. 
 
5.4.2. AMF studies of Fe@Au@LS-anthracene (21 and 25) 
 Fe@Au@LS1-anthracene NPs 21 and Fe@Au@LS2-anthracene NPs 25 were 
separately subjected to one 15-minute burst of AMF exposure at 500 A.  After the 
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exposure, the NPs were pelleted via centrifugation at 10K rpm for 5 min, and the 
supernatant was analyzed using MALDI-TOF. 
To confirm initial loading of LS2-anthracene, freshly loaded Fe@Au@LS2-
anthracene NPs 25 were incubated in 400 µL 0.1M DTT for 2 h at rt, pelleted via 
centrifugation at 10K rpm for 5 min, and the supernatant was analyzed using MALDI-
TOF. 
 
5.4.3. Preparation of Fe@Au@LS-PEG NPs 
Preparation of protected LS1-FITC 26 
FITC-CHO (112.2 mg, 0.24 mmol) was added to a 15 (143.3 mg, 0.24 mmol) in 
9:1 CHCl3:MeOH (3 mL) at room temperature and stirred overnight.  Upon completion 
as determined by TLC analysis, the reaction concentrated in vacuo to afford 26 (226.2 
mg, 90%) and was used without further purification.  1H NMR (500 MHz, DMSO-d6) 
δ 1.29 (s, 9H), 1.31- 1.52 (m, 6H), 1.57-1.76 (m, 2H), 2.06 (br s, 2H), 2.17-2.22 (m, 3H), 
2.96 (br s, 4H), 3.48-3.56 (m 2H), 3.80-3.84 (m, 2H), 4.02-4.06 (m, 2H), 4.35-4.26 (m, 
2H), 6.55-6.61 (m, 4H), 6.67 (s, 2H), 7.15-7.31 (m, 17H), 7.82-7.84 (m, 1H), 8.22 (s, 
1H), 10.12 (brs, 2H). 
 
Preparation of protected LS2-FITC 27 
FITC-CHO (522.7 mg, 1.1 mmol) was added to a 18 (526 mg, 1.1 mmol) in 9:1 
CHCl3:MeOH (5 mL) at room temperature and stirred overnight.  Upon completion as 
determined by TLC analysis, the reaction concentrated in vacuo to afford 27 (915.4 mg, 
89%) and was used without further purification.  1H NMR (500 MHz, DMSO-d6) δ 1.07-
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1.23 (m, 4H), 1.27-1.29 (m, 2H), 1.47-1.49 (m, 2H), 1.90 (br s, 2H), 2.01-2.09 (m, 4H), 
2.51 (s, 1H), 3.58-3.62 (m, 2H), 3.69-3.71 (m, 2H), 3.82-3.86 (m, 1H), 3.98-4.01 (m, 
2H), 4.21-4.22 (m, 2H), 5.79 (br s, 1H), 6.57-6.65 (m, 4H), 6.70 (s, 2H), 7.16-7.24 (m, 
11H), 7.28-7.39 (m, 6H), 7.85-7.87 (m, 1H), 8.10 (s, 1H), 10.12 (br s, 2H). 
 
Preparation of LS-FITC (28 and 29) 
To prepare LS1-FITC for loading onto Fe@Au NPs, protected LS1-FITC (95.7 
mg, 0.09 mmol) was dissolved in CH2Cl2 (1 mL) at 0 °C.  TFA (250 µL, 13 mmol) was 
added dropwise, followed by Et3SiH (43 µL, .27 mmol) added dropwise.  The mixture 
was stirred at 0 °C for 30 mins.  Upon completion as determined by TLC analysis, the 
reaction was warmed to rt, concentrated in vacuo, and used crude immediately for 
addition to NPs.  Both 28 and 29 followed this procedure. 
 
Preparation of Fe@Au-LS-FITC-PEG NPs (30 and 31) 
Following a modified procedure by Menichette et al.,13 PEG-SH (82.6 mg, 0.09 
mmol) was added to LS1-FITC 28 (18 mg, 0.09 mmol) in 9:1 CHCl3:MeOH (10 mL).  
This solution was added to rapidly stirring NPs (5 mg) in CHCl3 (10 mL), and the 
solution was stirred rapidly overnight.  The NPs were concentrated in vacuo and 
redissolved in EtOH (50 mL).  NPs were pelleted via centrifugation at 10K rpm for 15 
minutes.  The supernatant was discarded, the NPs were redissolved in H2O (50 mL) under 
sonication, pelleted via centrifugation at 10K rpm for 15 minutes, and the supernatant 
was discarded.  The NPs were resissolved in saturated sodium bicarbonate (50 mL) under 
sonication, pelleted via centrifugation at 10K rpm for 15 minutes, and the supernatant 
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was discarded.  The NPs were resissolved in 1X PBS buffer (50 mL, pH = 7.4) under 
sonication, pelleted via centrifugation at 10K rpm for 15 minutes, and the supernatant 
was discarded.  The NPs were resissolved in DI water (50 mL) under sonication, pelleted 
via centrifugation at 10K rpm for 15 minutes, and the supernatant was discarded.  This 
washing process with water was performed twice.  After the final discard of supernatant, 
the NPs were lyophilized and stored in solid form under nitrogen at rt until further use.   
Both 30 and 31 were prepared in this manner.  Fe@Au-LS1-FITC-PEG NPs 30 were 
characterized via UV-vis spectroscopy, ζ-potential, DLS, and SEM.  UV-vis showed a 
characteristic surface plasmon resonance band at 531 nm, indicating the presence of gold.  
The ζ-potential was 12.6 ± 0.212 mV.  This is not surprising because both LS1-FITC and 
PEG are neutral in water.  The DLS reading was 229.5 ± 0 nm, but the particles have an 
average diameter of 23 ± 7 nm based on SEM imaging (Figure 4.13). 
 
 
5.4.4. AMF studies of Fe@Au@LS-FITC-PEG NPs 
 A fresh batch of Fe@Au@LS1-FITC-PEG NPs 30 and Fe@Au@LS2-FITC-PEG 
NPs 31 were separately subjected to four sequential 15-minute bursts of AMF exposure 
at 500 A in 1 mL 1X PBS buffer (pH 7.4).  After each exposure, the NPs were pelleted 
via centrifugation at 10K rpm, 5 min, the supernatant was added to 2 mL fresh 1X PBS 
buffer in a cuvette, and then analyzed using a fluorometer.  Before each AMF exposure, 1 
mL of the liquid in the cuvette was added to the NP pellet and resuspended.  After the last 
reading, an aliquot of the supernatant was analyzed via MALDI-TOF (Figure 3e and 3f), 
then the NPs were incubated with 400 µL 0.1M DTT for 2 h at rt, pelleted via 
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centrifugation at 10K rpm, 5 min, and then analyzed using a fluorometer.  The DTT 
fluorescence reading was deemed “100% release”, and each reading prior gave % release 
based on this reading.  Each linker system testing was done in triplicate.   
A fresh batch of Fe@Au@LS1-PEG NPs 30 also was incubated for 2 hours, at 37 
°C and at 50 °C, then incubated with 400 µL 0.1M DTT for 2 h at rt followed by analysis 
using a fluorometer.  The DTT fluorescence reading was deemed “100% release”, and 
each reading prior gave % release based on this reading.  Each temperature study was 
performed in triplicate. 
 
5.4.5. Preparation of GNP@LS1-FITC NPs 
 LS1-FITC 28 (118.7 mg, 0.16 mmol) in 9:1 CHCl3:MeOH (20 mL) was added to 
rapidly stirring NPs (163.9 mg) in CHCl3 (50 mL), and the solution was stirred rapidly 
overnight.  The NPs were concentrated in vacuo and redissolved in EtOH (50 mL).  NPs 
were pelleted via centrifugation at 10K rpm for 15 minutes.  The supernatant was 
discarded, the NPs were redissolved in H2O (50 mL) under sonication, pelleted via 
centrifugation at 10K rpm for 15 minutes, and the supernatant was discarded.  The NPs 
were resissolved in saturated sodium bicarbonate (50 mL) under sonication, pelleted via 
centrifugation at 10K rpm for 15 minutes, and the supernatant was discarded.  The NPs 
were resissolved in 1X PBS buffer (50 mL, pH = 7.4) under sonication, pelleted via 
centrifugation at 10K rpm for 15 minutes, and the supernatant was discarded.  The NPs 
were resissolved in DI water (50 mL) under sonication, pelleted via centrifugation at 10K 
rpm for 15 minutes, and the supernatant was discarded.  This washing process with water 
was performed twice.  After the final discard of supernatant, the NPs were lyophilized 
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and stored in solid form under nitrogen at rt until further use.  GNP@LS1-FITC NPs 
were characterized via ζ-potential, DLS, and SEM.  ζ-potential  showed a surface charge 
of -20.6 ± 1.63 mV.  DLS readings gave an average hydrodynamic diameter of 226.8 ± 
26.77 nm, and SEM also shows aggregation of that size (Chapter 4, Figure 4.18a).  Each 
individual particle, though, was much smaller, as seen in Figure 4.18b.   
 
5.4.6. AMF Studies of Dual NP system 
For the dual NP system, 5 mg GNP@LS1-FITC was combined with an equal 
amount of MNP by weight (1:1), twice the amount of MNP by weight (1:2), and three 
times the amount of MNP by weight (1:3).   Each freshly prepared ratio was subjected to 
four sequential 15-minute bursts of AMF exposure at 500 A in 1 mL 1X PBS buffer (pH 
7.4).  After each exposure, the NPs were pelleted via centrifugation at 10K rpm for 5 min, 
the supernatant was added to 2 mL fresh 1X PBS buffer in a cuvette, and then analyzed 
using a fluorometer.  Before each AMF exposure, 1 mL of the liquid in the cuvette was 
added to the NP pellet and resuspended.  After each exposure, the NPs were pelleted via 
centrifugation at 10K rpm for 5 min, and the supernatant was analyzed using a 
fluorometer.  After the last reading, the NPs were incubated with 400 µL 0.1M DTT for 2 
h at rt, pelleted via centrifugation at 10K rpm for 5 min, and the supernatant was analyzed 
using a fluorometer.  The DTT fluorescence reading was deemed “100% release”, and 
each reading prior gave % release based on this reading.  Each dual NP system testing 
was done in triplicate.   
 A freshly prepared batch of each ratio of the dual NP system was also subjected to 
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AMF exposure at 300 A.  The method remained the same as previously described, but the 
amperage was lowered to 300 A.   
A freshly prepared batch of each ratio was incubated at 37 °C for 2 hours, pelleted 
via centrifugation at 10K rpm for 5 min, and the supernatant was analyzed using a 
fluorometer.  The NPs were then incubated with 400 µL 0.1M DTT for 2 h at rt, pelleted 
via centrifugation at 10K rpm for 5 min, and the supernatant was analyzed using a 
fluorometer.  The DTT fluorescence reading was deemed “100% release”, and each 
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My first two years of graduate school were devoted to a project unrelated to the present 
thesis.  The focus during this time was synthesis and application of an isotopically 
labeled reagent for chemoselective capture of carbonyls for multiplex analysis.  This 
research served as a platform for me to experience multistep synthesis, methods of 
compound purification, spectral analyses, and aminooxy chemistry, which came in handy 
once I began my thesis work.  I have included the publication that resulted from the 
efforts during this time.  The work shows how we designed a reagent N-methoxy-N-(2-
aminooxyethyl)-propionate (MAP) to increase stability toward hydrolysis and acyl 
transfer.  Because amides do not readily undergo α-cleavage as easily as esters, we used a 
methoxy amine moiety so that, upon α-cleavage, the nitrogen radical formed would be 
more stable, thus promoting α-cleavage (Scheme 2).  In this manuscript, we describe the 
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A.3. List of abbreviations 
 
h = hour 
rt = room temperature 
mmol = millimole 
mg = milligram 
TLC = thin layer chromatography 
rb = round bottom 
rpm = revolutions per minute 
EtOH = ethanol 
CH2Cl2 = dichloromethane 
CHCl3 = chloroform 
TFA = trifluoroacetic acid 
MeOH = methanol 
nm = nanometer 
MRI = magnetic resonance imaging 
NMR = nuclear magnetic resonance 
FTIR = fourier transform infrared radiation 
HRMS = high resolution mass spectrometry 
ATR = attenuated total reflectance  
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